

DECLARATION

I, Natsuo TANAKA of HIRAKI & ASSOCIATES, do solemnly and sincerely declare as follows:

1. That I am well acquainted with the English and Japanese languages and am competent to translate from Japanese into English.
2. That I have executed, with the best of my ability, a true and correct translation into English of Japanese Patent Application No. 314489/2001 filed on October 11, 2001, a copy of which I attach herewith.

This 23rd day of August, 2007

N. Tanaka
Natsuo TANAKA

SPECIFICATION

Anti-TRAIL-R antibody

FIELD OF THE INVENTION

The present invention relates to an anti-TRAIL receptor (TRAIL-R) antibody recognizing a TRAIL receptor 1 (TRAIL-R1) or a TRAIL receptor 2 (TRAIL-R2), which are cell membrane molecules involved in apoptosis.

Furthermore, the present invention relates to a prophylactic or therapeutic agent, which contains anti-TRAIL-R antibody as an active ingredient and is used against diseases caused by cells expressing TRAIL-R, and in particular relates to a therapeutic agent used against malignant tumors.

BACKGROUND OF THE INVENTION

In the living body, physiological cell death caused by normal cell alternation is referred to as apoptosis, and is distinguished from necrosis, which is pathological cell death [see Kerr, et al. (1972) Br. J. Cancer 26, 239]. Apoptosis is the phenomenon generally observed in the process of, for example, embryogenesis and the selection of lymphocytes (T cells and B cells) [see Itoh, S., et al. (1991) Cell 66, 233-243]. It is thought that when cells which should originally be eliminated by apoptosis are not removed, this may cause cancer, lupus, herpes virus infection, and other problems. Moreover, when cells that originally should survive are eliminated by apoptosis, this can cause diseases and pathological conditions such as AIDS, Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, multiple sclerosis, retinitis pigmentosa, aplastic anemia, myocardial infarction, cerebral apoplexy or toxic substances-induced hepatopathy [see Kataoka, S., et al. (1996) The Oncologist 1, 399-401].

During apoptosis, characteristic phenomena such as curved cell surfaces, condensation of nuclear chromatin, fragmentation of chromosomal DNA, and

loss of mitochondrial function are observed. Various intrinsic and extrinsic signals are thought to cause these cellular changes. As intrinsic signals, it has been reported that oncogenes such as myc and bcl-2 and tumor suppressor genes such as p53 are involved in apoptosis induction [see KATAOKA et al., (1993) JIKKEN IGAKU 11, 17, 2324-2328]. As extrinsic signals, it is known that chemotherapy drugs, radiation or the like induces apoptosis [see KATAOKA et al., (1994) SAISSHIN IGAKU 49, 6, 1152-1157].

As molecules involved in such apoptosis, molecules belonging to tumor necrosis factor family (TNF family) such as tumor necrosis factor- α (TNF- α), tumor necrosis factor- β (TNF- β) and Fas ligand have been identified. TNF- α and TNF- β have been reported to induce apoptosis in carcinoma cells [see Schmid et al., (1986) Proc. Natl. Acad. Sci. 83, 1881; see Dealtry et al., (1987) Eur. J. Immunol. 17, 689]. Since mice having mutant Fas or Fas ligands develop the conditions of autoimmune disease, it has been strongly suggested that the Fas ligands have a function of eliminating self-reactive lymphocytes by apoptosis in the periphery [see Krammer, et al., (1994) Curr. Op. Immunol. 6, 279-289; see Nagata, et al., (1995) Science 267, 1449-1456]. It has been reported that agonistic mouse monoclonal antibodies that bind specifically to Fas exert apoptosis-inducing activity against carcinoma cells to the same level as that exerted by TNF- α [Yonehara, et al., (1989) J. Exp. Med. 169, 1747-1756].

These TNF family molecules transmit signals into cells by binding to specific receptors on the cell surfaces. Plural receptors for TNF family molecules are known, and they are referred to as TNF receptor family molecules.

TNF receptor family molecules are defined by the presence of cysteine-rich repetition of an extracellular domain. Among them, Fas and TNFR1, which are receptors of a Fas ligand and a TNF- α , contain within the cells a region referred to as a "death domain" sharing homology with reaper, a

Drosophila suicide gene [see Golstein, P., et al. (1995) *Cell* 81, 185-186; see White, K., et al. (1994) *Science* 264, 677-683] and such death domain is essential for signal transduction for apoptosis. Activation of Fas promotes the association of an adapter molecule FADD/MORT1 containing the death domain, and induces the activation of caspase-8 bound to FADD/MORT1. The activated caspase-8 activates downstream caspase molecules in sequence, thereby finally leading the cells to apoptosis [see Nagata, S., (1997) *Cell* 88, 355-365].

Recently, a novel TNF family molecule that induces apoptosis has been found. Wiley et al., [see *Immunity* (1995) 3, 673-682] named the molecule "TNF-related apoptosis-inducing ligand" or briefly "TRAIL." This molecule is also referred to as "Apo-2 ligand" or "Apo-2L" [see Pitt, R. M., et al. (1996) *J. Biol. Chem.* 271, 12687-12690]. For convenience, this molecule is referred to as TRAIL in this specification.

Unlike the Fas ligand, TRAIL is detected at a significant level in many human tissues (e.g., spleen, lungs, prostate, thymus, ovary, small intestine, large intestine, peripheral blood lymphocyte, placenta and kidney). TRAIL is constitutively transcribed in some cell lines. TRAIL has also been shown to rapidly activate apoptosis at a significantly faster pace than that induced by TNF, within a time frame resembling death signal transduction by Fas [see Marsters, S. A., et al., (1996) *Curr. Biol.* 6, 750-752].

Now 5 proteins have already been identified as TRAIL receptors. Two receptors, TRAIL-R1/DR4 and TRAIL-R2/DR5, have both been reported to have death domains within the intracellular regions. The transcript of TRAIL-R1 is recognized in many human tissues including the spleen, peripheral blood leukocytes, small intestine and the thymus. The transcript of TRAIL-R2 has been detected in many tissues including the spleen, peripheral blood lymphocytes and the ovary [see Pan, G., et al. (1997) *Science* 276, 111-113; see Pan, G., et al. (1997) *Science* 277, 815-818 ; see Walczak, H., et al. (1997)

EMBO J 16 (17) 5386-5397].

The presence of the two forms of TRAIL-R2 resulting from alternative splicing and the high expression amount of TRAIL-R2 comprising 440 amino acids in carcinoma cells has been reported [see Scream, G. R., et al., (1997) Curr Biol 7 (9), 693-696 ; see Arai, T., et al., (1998) Cancer Letters 133, 197-204].

Recombinant human TRAIL is a recombinant protein comprising the extracellular region of TRAIL, and has been reported to induce apoptosis in many types of carcinoma cells [see Griffith, T. S., et al. (1998) Curr. Opin. Immunol., 10, 559-563].

Furthermore, the recombinant human TRAIL has exerted an effect on a tumor-bearing mouse model using human colon carcinoma cells and breast carcinoma cells [see Walczak, H., et al. (1999) Nature Medicine 5, 2, 157-163]. Unlike TNF- α or FAS ligands also belonging to the TNF receptor family and having apoptosis-inducing activity, TRAIL did not provide damage to the normal tissues of mice or cynomolgus monkeys [see Ashkenazi, A., et al. (1999) J. Clin. Invest. 104, 155-162].

Based on these reports, it is thought that TRAIL selectively induces death in tumor cells. However, such selectivity has not yet been supported theoretically since TRAIL receptors are also expressed in normal cells. Moreover, the recombinant human TRAIL has recently been reported to induce apoptosis in normal human hepatocytes [see Jo, M., et al. (2000) Nature Medicine 6, No.5, 564-567] and reported to induce apoptosis also in human brain cells [see Nitsch, R., et al. (2000) The Lancet 356, 827-828]. Because agonistic anti-Fas antibodies, which induce apoptosis in hepatocytes, induce fulminant hepatitis in a very short time and thus cause death in mice and chimpanzees, cell death induction by TRAIL on hepatocytes has attracted attention as a particularly significant issue. The safety of using TRAIL as a pharmaceutical product for humans has been questioned [see Nagata, S., (2000)

Nature Medicine 6, 5, 502-503].

It has also been reported that the presence or absence of the cell-death-inducing activity of TRAIL on hepatocytes depends on the type of recombinant TRAIL protein [see Lawrence, D., et al. (2001) Nature Medicine 7, 4, 383-385]. However, the safety of the recombinant TRAIL protein is still being studied.

Recently, anti-Fas antibodies that do not induce hepatopathy when administered to mice have been reported for the first time [see Ichikawa, K., et al. (2000) International Immunology 12, No.4, 555-562]. There have been no known recombinant Fas ligands confirmed not to induce hepatopathy. This suggests that antibodies having activity that may be unavailable from ligands can be obtained. However, the theoretical background of the reason that the antibodies show no hepatotoxicity in spite of inducing apoptosis in T cells has not been revealed. For example, in the case of a different antigen such as TRAIL, it has not been demonstrated whether or not agonistic antibodies having no toxicity can be obtained.

TRAIL binds to TRAIL-R1, TRAIL-R2, or both, and induces apoptosis as described above. However, via which receptor the signals to induce apoptosis in hepatocytes are introduced by TRAIL has not been shown. Furthermore, no research has been done based on the idea of whether hepatotoxicity can be avoided by adding TRAIL-R1/R2 selectivity to agonistic antibodies.

An effective therapeutic means against malignant tumors involves removing carcinoma cells and protecting normal tissues or cells. A drug whose action mechanism is apoptosis induction by the recombinant human TRAIL may cause damages to normal tissues, particularly the liver and the brain, even if it is able to remove carcinoma cells.

Currently, monoclonal antibodies such as a chimeric antibody targeting CD20, which is a receptor present on the cell membrane, and a humanized

antibody targeting Her2/neu are used against malignant tumors as target diseases, and their therapeutic effects have been recognized. Since antibodies have characteristics including a long half-life in blood and high specificity to antigens, they are particularly useful as anti-tumor agents. For example, in the case of antibodies targeting tumor-specific antigens, the administered antibodies are assumed to accumulate in tumors. Thus, attack against carcinoma cells by the immune system can be expected by complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. In addition, the binding of a drug such as a radionuclide, a cytotoxic substance or the like to the antibodies enables the efficient delivery of the drug bound to the antibody to tumor sites. At the same time, reduced side effects can be expected due to decreased amounts of the drug having reached other non-specific tissues. When tumor-specific antigens have activity to induce cell death, antibodies having agonistic activity are administered, and when tumor-specific antigens are involved in cell proliferation and survival, antibodies having neutralization activity are administered. And then, the accumulation of tumor-specific antibodies and suppression of tumor growth or regression of tumors due to the activity of the antibodies can be expected.

It is thought to be appropriate to apply antibodies as anti-tumor agents because of the characteristics described above. In addition, if antibodies are those against TRAIL receptors, antibodies that may be obtained can avoid causing damage to the liver, which is unable to avoid with the recombinant human TRAIL, and have equivalent apoptosis-inducing activity against carcinoma cells. However, such antibodies have not been reported so far.

SUMMARY OF THE INVENTION

A first purpose of the present invention is to provide a novel antibody which has not been reported so far or a molecule analogous thereto, which is capable of binding to human TRAIL-R1 and/or human TRAIL-R2 and induces

apoptosis specifically in carcinoma cells, without inducing damage to normal human hepatocytes to which a recombinant human TRAIL protein can cause damages. A second purpose of the present invention is to provide a prophylactic or therapeutic agent comprising the above antibody or a molecule analogous thereto as an active ingredient against various malignant tumors including solid tumors that are currently difficult to treat.

As a result of intensive studies on the production of antibodies against human TRAIL-R1 and -R2, we have succeeded in obtaining monoclonal antibodies from the culture supernatant by immunizing transgenic mice capable of producing human antibodies by genetic engineering techniques with human TRAIL-R1 or R2, generating hybridomas producing novel monoclonal antibodies that bind to TRAIL-R1 and/or TRAIL-R2 using the method of Kohler and Milstein et al. [see (1975) *Nature* 256, 495], which is generally used in monoclonal antibody production.

Furthermore, we have completed the present invention by finding that the novel monoclonal antibodies induce apoptosis specifically in carcinoma cells by binding to TRAIL-R1 and/or R2 present on the surfaces of carcinoma cells.

The present invention is as follows.

(1) An antibody or a functional fragment thereof, binding to TRAIL-R1 and/or TRAIL-R2.

The above antibody or the functional fragment thereof has at least one property selected from the following (a) to (c) of:

- (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;
- (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and
- (c) not inducing human hepatocyte toxicity.

In the present invention, an antibody or a functional fragment thereof having all the above properties (a) to (c) is preferred. Furthermore, the antibody or the functional fragment thereof of the present invention also includes an antibody or a functional fragment thereof that has at least one property of the above (a) to (c), and binds to TRAIL-R2, but does not bind to TRAIL-R1.

(2) The above antibody is a monoclonal antibody produced by a mouse-mouse hybridoma, such as E-11-13, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-12, F-4-8 or G-3-10, and is preferably a human antibody. The type of the monoclonal antibody produced by E-11-13, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-12 or F-4-8 is the immunoglobulin G(IgG), and the type of the monoclonal antibody produced by G-3-10 is the immunoglobulin M(IgM). These monoclonal antibodies include an antibody the activity of inducing apoptosis of cancer cells of which is enhanced or not enhanced in coexistence with TRAIL. Hybridoma H-48-2 is deposited with the accession No. of FERM BP-7599, hybridoma F-4-8 is deposited with the accession No. of FERM BP-7699 and hybridoma L-30-10 is deposited with the accession No. of FERM BP-7700.

Examples of carcinoma cells include colon carcinoma cells, Colo205, glioma U251 cells and T cell lymphoma Jurkat cells. The carcinoma cells are appropriately selected from these cells.

(3) The antibody or the functional fragment thereof of the present invention has, under conditions where the number of cells is 7.5×10^4 and the reaction time is 24 hours, an LD50 value for human hepatocytes of 0.01 $\mu\text{g}/\text{ml}$ or more, preferably 0.1 $\mu\text{g}/\text{ml}$ or more, further preferably 2 to 10 $\mu\text{g}/\text{ml}$, or most preferably 10 $\mu\text{g}/\text{ml}$ or more. In the meantime, the antibody or the functional fragment thereof of the present invention has, under conditions where the number of cells is 2.5×10^3 and the reaction time is 48 hours, an LD50 value for carcinoma cells (e.g., Colo205 cells) of 100 $\mu\text{g}/\text{ml}$ or less, preferably 10 $\mu\text{g}/\text{ml}$

or less, more preferably 0.7 $\mu\text{g}/\text{ml}$ or less, further preferably 0.02 to 0.11 $\mu\text{g}/\text{ml}$, or most preferably 0.02 $\mu\text{g}/\text{ml}$ or less. Moreover, the antibody or the functional fragment thereof that is particularly preferred in the present invention has a combination of LD50 values, one of which is between 2 and 100 $\mu\text{g}/\text{ml}$ for human hepatocytes under conditions where the number of cells is 7.5×10^4 and the reaction time is 24 hours, and the other of which is between 0.02 and 0.11 $\mu\text{g}/\text{ml}$ for carcinoma cells under conditions where the number of cells is 2.5×10^3 and the reaction time is 48 hours.

(4) Furthermore, the antibody or the functional fragment thereof of the present invention has an LD50 value for human hepatocytes under conditions where the number of cells is 7.5×10^4 and the reaction time is 24 hours that is 2 times or more, preferably 10 times or more, more preferably 50 times or more, further preferably 50 times to 100, or most preferably 100 times or more greater than that for carcinoma cells under conditions where the number of cells is 2.5×10^3 and the reaction time is 48 hours.

(5) Furthermore, the antibody or the functional fragment thereof of the present invention can suppress the growth of tumors (e.g., those derived from Colo205 cells transplanted to nude mice) or regress tumors. In this case, a period during which tumor cell proliferation can be suppressed, or during which tumor regression can be achieved when the antibody or the functional fragment thereof of the present invention is administered, is at least 9 days, preferably at least 11 days or further preferably at least 13 days. Hereinafter, the period, in order of preference, is as follows: at least 30 days, at least 60 days, and most preferably at least 120 days. In addition, the dose of the antibody or the functional fragment thereof of the present invention that is administered to a tumor-bearing animal to be tested (e.g., a body weight of a tumor-bearing experimental animal is 20 g) is between 0.1 $\mu\text{g}/\text{body}$ (5 $\mu\text{g}/\text{kg}$) and 100 $\mu\text{g}/\text{body}$ (5 mg/kg), preferably between 0.1 $\mu\text{g}/\text{body}$ and 100 $\mu\text{g}/\text{body}$. For example, the dose is 100 $\mu\text{g}/\text{body}$ or 5 mg/kg, preferably 20 $\mu\text{g}/\text{body}$ or 1 mg/kg, more preferably 4 $\mu\text{g}/\text{body}$ or

200 µg/kg, or further preferably 1 µg/body or 50 µg/kg. A dose of 0.5 µg/body (25 µg/kg) may also be administered. The administration frequency is, for example, once to 3 times per week, or administration is performed on alternate days.

Examples of the relevant tumor include at least one tumor selected from the group consisting of colon cancer, colorectal cancer, lung cancer, breast cancer, brain tumor, malignant melanoma, renal cell carcinoma, leukemia, lymphomas, T cell lymphomas, gastric cancer, pancreas cancer, cervical cancer, endometrial carcinoma, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, cutaneous cancer, urinary tract carcinoma, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecomatosis, androblastoma, endometrium hyperplasy, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, angioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendrolioma, medulloblastoma, ganglioneuroblastoma, glioma, rhabdomyosarcoma, hamartoblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma and Wilms tumor.

- (6) A hybridoma producing monoclonal antibodies that bind to TRAIL-R2, which is selected from the group consisting of E-11-13, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-12, F-4-8 and G-3-10.
- (7) A method for producing anti-TRAIL-R2 monoclonal antibodies, comprising culturing the above hybridoma and collecting the antibodies binding to TRAIL-R2 from the obtained culture product.
- (8) A method for producing anti-TRAIL-R2 monoclonal antibodies, comprising isolating a gene encoding a monoclonal antibody from the above hybridoma, constructing an expression vector having the gene, introducing the expression vector into a host to express the above monoclonal antibody, and collecting

anti-TRAIL-R2 monoclonal antibodies from the host, or the culture supernatant or the secretion of the obtained host.

Examples of a host include any host selected from the group consisting of *Escherichia coli*, yeast cells, insect cells, mammalian cells and plant cells, and mammals.

(9) A method for producing anti-TRAIL-R2 antibody which does not have hepatocyte toxicity, comprising selecting an antibody which does not bind to TRAIL-R1 from the population of antibodies which bind to TRAIL-R2.

(10) A prophylactic or therapeutic agent against tumors, comprising as an active ingredient the above antibody or the functional fragment thereof.

Examples of the tumor include at least one tumor selected from the group consisting of colon cancer, colorectal cancer, lung cancer, breast cancer, brain tumor, malignant melanoma, renal cell carcinoma, leukemia, lymphomas, T cell lymphomas, gastric cancer, pancreas cancer, cervical cancer, endometrial carcinoma, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, cutaneous cancer, urinary tract carcinoma, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecomatosis, androblastoma, endometrium hyperplasy, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, angioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendrolioma, medulloblastoma, ganglioneuroblastoma, glioma, rhabdomyosarcoma, hamartoblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma and Wilms tumor.

The present invention is explained in detail as follows.

The anti-TRAIL-R1 and R2 monoclonal antibodies have been reported to have activity to induce apoptosis in carcinoma cells [see Griffith, T. S., et al. (1999) *J. Immunol.* 162, 2597-2605; see Chunthrapai, A., et al. (2001) *J. Immunol.* 166, 4891-4898]. However, these antibodies are derived from mice.

In addition, the cytotoxicity against normal human hepatocytes, which is also questioned in a recombinant human TRAIL protein, is a concern.

Surprisingly, the novel human anti-TRAIL-R2 monoclonal antibody of the present invention has been revealed to have no side effect of inducing cytotoxicity against not only cells derived from a normal human tissue, but also normal hepatocytes for which cytotoxicity by the recombinant human TRAIL protein is a concern. We have obtained a novel anti-TRAIL-R2 monoclonal antibody which is specific to the TRAIL-R2. That is, we have completed the present invention by succeeding for the first time in the world in producing a novel monoclonal antibody provided with possible advantages of improved safety and therapeutic effects. The monoclonal antibody is preferably a whole human antibody. Its antigenicity, which is always a problem in the case of a mouse-derived antibody, has already been avoided.

Any antibody type of immunoglobulin G(IgG), A(IgA), E(IgE) or M(IgM) can be appropriately used as the antibody. Normally, IgG is more preferred.

The present invention is explained in detail by making clear the meanings of the words and phrases used in the present invention as follows.

1. TRAIL and the antibody

The antibody of the present invention is an antibody against the receptor of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (TRAIL-R). The antibodies of the present invention are (1) an antibody reacting with TRAIL-R1, (2) an antibody reacting with TRAIL-R2, and (3) an antibody reacting with both TRAIL-R1 and TRAIL-R2. In the present invention, the antibody (1) may be referred to as "the anti-TRAIL-R1 antibody," and the antibodies (2) and (3) may be referred to as "the anti-TRAIL-R2 antibodies." In addition, when both TRAIL receptors, TRAIL-R1 and TRAIL-R2, are conveniently explained together in this specification, they may

be referred to as "TRAIL-R1 and R2." Therefore, for example, the description of "TRAIL-R1 and R2 expression vectors" (see Example 1, below) is meant to explain two expression vectors, the expression vector of TRAIL-R1 and the expression vector of TRAIL-R2.

The "antibody" in the present invention is an antibody or a part thereof having reactivity to the human TRAIL-R1 and R2 or a part thereof as defined above, and includes functional fragments of these antibodies. The "functional fragment" means a part (partial fragment) of the antibody retaining one or more actions of the antibody on an antigen. Specific examples of functional fragments include $F(ab')_2$, Fab', Fab, Fv, disulfide-bound Fv, single chain Fv(scFv) and the polymers thereof (D. J. King., Applications and Engineering of Monoclonal Antibodies., 1998 T. J. International Ltd).

The "human antibody" in the present invention means an antibody which is the expression product of a human-derived antibody gene.

Examples of the antibody of the present invention include various antibodies having a property of inducing apoptosis in carcinoma cells expressing the human TRAIL-R1 and R2 as later described in Example 7.

The antibody of the present invention encompasses a monoclonal antibody comprising heavy chains and/or light chains having amino acid sequences with deletion, substitution or addition of one or a plurality of amino acids in each amino acid sequence of the heavy chain and/or light chain of the antibody. The above-described partial amino acid alteration (deletion, substitution, insertion or addition) can be introduced into the amino acid sequence of the antibody of the present invention by, for example, a method which involves partial alteration of the nucleotide sequence encoding the amino acid sequence. The partial alteration can be introduced into the nucleotide sequence by a standard method using known site-specific mutagenesis (Proc Natl Acad Sci USA., 1984 Vol 81: 5662). Here, the antibody is an immunoglobulin wherein all the regions, including a heavy chain variable region

and a heavy chain constant region, and a light chain variable region and a light chain constant region composing the immunoglobulin, are derived from a gene encoding the immunoglobulin.

The antibody of the present invention also encompasses antibodies having any immunoglobulin classes and isotypes.

The anti-TRAIL-R1 and R2 antibodies of the present invention can be produced by the following production method. Specifically, for example, the above-defined human TRAIL-R1 and R2 or a part thereof is bound to an appropriate substance (e.g., bovine serum albumin) for enhancing the antigenicity of an antigen, and then non-human mammals including human antibody-producing transgenic mice and the like are immunized with the bound product, together with an immunopotentiator (e.g., Freund's complete or incomplete adjuvant) if necessary. Alternatively, immunization can also be performed by introducing a gene encoding the human TRAIL-R1 or human TRAIL-R2, and then administering animal cells excessively expressing TRAIL-R1 or TRAIL-R2 on the cell surfaces. Monoclonal antibodies can be obtained by culturing hybridomas that are obtained by fusing antibody-producing cells obtained from immunized animals with myeloma cells incapable of producing autoantibodies, and then selecting clones that produce monoclonal antibodies showing specific affinity for the antigens used for immunization.

The antibody of the present invention encompasses an antibody converted to have a different subclass by alteration using genetic engineering techniques known to a person skilled in the art. For example, the subclass switching of the antibody of the present invention to IgG2 or IgG4 enables antibodies with a low binding activity to Fc receptors to be obtained. Also, the subclass switching of the antibody of the present invention to IgG1 or IgG3 enables antibodies with a high binding activity to Fc receptors to be obtained. Moreover, the binding activity to a Fc receptor can also be changed by

artificially altering the amino acid sequence of the constant region of the antibody of the present invention, or by binding with a constant region sequence having such an altered sequence. Furthermore, the therapeutic effect against diseases such as cancer can be further enhanced by binding to the antibody of the present invention a radionuclide such as iodine, yttrium, indium or technetium, (J. W. Goding, *Monoclonal Antibodies: principles and practice.*, 1993 Academic Press), bacterial toxin such as pyocyanic toxin, diphtheria toxin or lysin, chemotherapeutics such as methotrexate, mitomycin or calicheamicin (D. J. King, *Applications and Engineering of Monoclonal Antibodies.*, 1998 T. J. International Ltd.; M. L. Grossbard., *Monoclonal Antibody-Based Therapy of Cancer.*, 1998 Marcel Dekker Inc), or else a prodrug such as Maytansinoid (Chari et al., *Cancer Res.*, 1992 Vol. 52: 127; Liu et al., *Proc. Natl. Acad. Sci. USA*, 1996 Vol. 93: 8681).

Moreover, we have found that the antibodies of the present invention having the property of binding to TRAIL-R2 but not the property of binding to TRAIL-R1 include antibodies that do not induce human hepatocyte toxicity. Therefore, the present invention also provides a method for producing anti-TRAIL-R2 antibodies having no hepatocyte toxicity, comprising a step of selecting antibodies that do not bind to TRAIL-R1 from the antibody population that binds to TRAIL-R2. However, the antibody of the present invention having no hepatocyte toxicity is not limited to an antibody having the property of binding to TRAIL-R2 but not the property of binding to TRAIL-R1.

The present invention encompasses the following operation steps in monoclonal antibody production. Specifically, the steps are, for example: (1) purification of biopolymers and/or the preparation of cells excessively expressing antigen proteins on the cell surfaces (these biopolymers and/or cells are used as immunogens); (2) immunization of animals by the injection of an antigen, blood collection, testing of the antibody titer, and determination of a time for excising the spleen and the like followed by preparation of

antibody-producing cells; (3) preparation of myeloma cells (hereinafter referred to as "myeloma"); (4) cell fusion of the antibody-producing cells with myeloma, (5) selection of a hybridoma group producing a target antibody; (6) division into a single cell clone (cloning); (7) if necessary, culture of hybridomas for producing monoclonal antibodies in large quantities, or breeding of animals having the hybridomas transplanted therein; and (8) study of the physiological activities and the recognition specificity of the thus-produced monoclonal antibodies, or testing of the characteristics as a labeled reagent.

The production method of anti-TRAIL-R1 and R2 monoclonal antibodies is described in detail according to the above steps, but the production method of the antibody is not limited to this method. For example, antibody-producing cells and myeloma other than splenocytes can also be used.

(1) Purification of antigen

As the antigen, a fusion protein of the extracellular regions of human TRAIL-R1 and R2 with the Fc region of a human IgG (hereinafter referred to as TRAIL-R1-hFc and TRAIL-R2-hFc) can be used. TRAIL-R1-hFc and TRAIL-R2-hFc can be obtained by integrating a DNA encoding a fusion protein of TRAIL-R1 or R2 with the Fc region of a human IgG into an expression vector for animal cells, introducing the expression vector into animal cells, and then purifying from the culture supernatant of the obtained transfectant strain. Alternatively, TRAIL-R1-hFc and TRAIL-R2-hFc commercially available from ALEXIS and the like can also be used. Furthermore, purified TRAIL-R1 and R2 from the cell membranes of a human cell line, can also be used as the antigen. Furthermore, the primary structures of TRAIL-R1 and R2 are known [see Pan, G., et al. (1997) *Science* 276, 111-113 and *Science* 277, 815-818 ; see Walczak, H., et al. (1997) *EMBO J* 16 (17) 5386-5397]. Thus, according to a method known by a person skilled in the art, peptides are chemically synthesized from the amino acid sequences of TRAIL-R1 and R2, and then can also be used as the

antigen.

As the immunogen, Cells which are transfected with the expression vectors pEF-TRAIL-R1delta and pEF-TRAIL-R2delta, which contain a DNA encoding human TRAIL-R1 and R2 deleting the death domain and the amino acids on the C-terminal side from the death domain in the intracellular region (hereinafter referred to as "TRAIL-R1 and R2delta"), into L929 cells and excessively express TRAIL-R1 and R2delta on the cell surfaces are effective. . pEF-TRAIL-R1delta and pEF-TRAIL-R2delta can be prepared by respectively integrating a DNA encoding a human TRAIL-R1delta protein and a DNA encoding a human TRAIL-R2delta protein into pEFneo, expression vectors for animal cells [see Ohashi. H., et al. (1994) Proc. Natl. Acad. Sci. 91, 158-162]. The DNAs encoding TRAIL-R1 and R2, vector, host and the like are not limited thereto.

Specifically, the transfectant strain obtained by transfecting L929 cells with pEF-TRAIL-R1 and R2delta is cultured. Using as indicators the neomycin resistance trait acquired by the cells having pEFneo vectors inserted therein and the confirmation of the expression of TRAIL-R1 and R2delta using goat anti-TRAIL-R1 and R2 polyclonal antibodies (DAKO), L929 cells excessively expressing human TRAIL-R1 and R2delta on the cell surfaces can be prepared.

(2) Preparation step of antibody-producing cell

The antigen obtained in (1), Freund's complete or incomplete adjuvant or an assistant such as potassium aluminum sulfate are mixed, and then experimental animals are immunized with the mixture as an immunogen. Transgenic mice capable of producing human-derived antibodies are most preferably used as experimental animals, and such mice are described in the publication of Tomizuka et al [Tomizuka. et al., Proc Natl Acad Sci USA., 2000 Vol 97: 722].

The method for administering immunogens upon mouse immunization may be any of subcutaneous injection, intraperitoneal injection, intravenous injection, intracutaneous injection, intramuscular injection or footpad injection. Intraperitoneal injection, footpad injection or intravenous injection is preferred.

Immunization can be performed once, or repeatedly (multiple times) at appropriate intervals (intervals of preferably 3 days to 1 week). Subsequently, the antibody titer against the antigen in the serum of the immunized animal is measured, and the animals showing sufficiently increased antibody titers are used as a source of antibody-producing cells, so that the effect of the following steps can be enhanced. Generally, antibody-producing cells derived from animals 3 to 5 days after the final immunization are preferably used for the following cell fusion step.

Examples of the method for measuring antibody titer that is used herein include various known techniques such as the radioimmunoassay (hereinafter referred to as "RIA method"), enzyme-linked immunosorbent assay (hereinafter, referred to as "ELISA method"), fluorescent antibody method and passive haemagglutination method. In view of, for example, detection sensitivity, promptness, correctness, and possibility of automation of the operation, the RIA method or the ELISA method is more preferred.

In the present invention, antibody titer can be measured by the following procedures according to, for example, the ELISA method. First, purified or partially purified recombinant human TRAIL-R1 and R2 are adsorbed on the surface of a solid phase such as a 96-well plate for ELISA. The solid phase surface, on which no antigen is adsorbed, is further coated with a protein, which is independent of the antigen, such as bovine serum albumin (hereinafter referred to as "BSA"). After the surface is washed, it is allowed to come into contact with a sample (e.g., mouse serum) that has been subjected to serial dilution as a primary antibody. Anti-TRAIL-R1 and R2 antibodies in the sample are bound to the above antigen. As a secondary antibody, enzyme-labeled

antibodies against human antibodies are added and bound to the human antibodies. After washing, the substrate of the enzyme is added, and then changes and the like in absorbance due to color development resulting from substrate degradation are measured. By this method, antibody titer is calculated.

(3) Preparation step of myeloma

As myeloma, cells incapable of producing autoantibodies and derived from mammals such as mice, rats, guinea pigs, hamsters, rabbits or humans can be used. In general, established cell lines obtained from mice, for example, 8-azaguanine-resistant mouse (derived from BALB/c) myeloma strains P3X63Ag8U.1 (P3-U1) [Yelton, D.E. et al. Current Topics in Microbiology and Immunology, 81, 1-7 (1978)], P3/NSI/1-Ag4-1(NS-1) [Kohler, G. et al. European J. Immunology, 6, 511-519 (1976)], Sp2/O-Ag14(SP-2) [Shulman, M. et al. Nature, 276, 269-270 (1978)], P3X63Ag8.653 (653) [Kearney, J. F. et al. J. Immunology, 123, 1548-1550 (1979)] and P3X63Ag8 (X63) [Horibata, K. and Harris, A. W. Nature, 256, 495-497 (1975)] are preferably used. These cell lines are sub-cultured in, for example, a 8-azaguanine medium [the medium prepared by adding 8-azaguanine to an RPMI-1640 medium supplemented with glutamine, 2-mercaptoethanol, gentamicin and fetal calf serum (hereinafter referred to as "FCS")], Iscove's Modified Dulbecco's Medium (hereinafter referred to as "IMDM") or Dulbecco's Modified Eagle Medium (hereinafter referred to as "DMEM"). Subculture is performed using a normal medium 3 to 4 days before cell fusion (e.g., DMEM medium containing 10% FCS), and 2×10^7 or more cells are ensured at the day of cell fusion.

(4) Cell fusion

Antibody-producing cells are plasma cells, or lymphocytes that are progenitor cells thereof, and may be obtained from any site of an individual. In

general, the cells can be obtained from, for example, the spleen, lymph node, bone marrow, tonsil, peripheral blood or an appropriate combination thereof. Splenocytes are most generally used.

After the final immunization, for example, the spleen, which is a site where antibody-producing cells are present, is excised from the mouse from which a given antibody titer is obtained, thereby preparing splenocytes, the antibody-producing cells. Currently, the most generally employed means for fusing the splenocytes with the myeloma obtained in step (3) is a method using polyethylene glycol, which has a relatively low cytotoxicity and with which the fusion procedure is simple. For example, this method comprises the following steps.

Splenocytes and myeloma are washed well in a serum-free medium (e.g., DMEM) or a phosphate-buffered saline (hereinafter referred to as "PBS"), and then mixed well to have a cell number ratio of splenocytes to myeloma of approximately 5:1 to 10:1, followed by centrifugation. The supernatant is removed, and then the precipitated cell groups are well disassembled. 1 ml of a 50% (w/v) polyethylene glycol (molecular weight of 1000 to 4000)-containing serum-free medium is dropped onto the precipitate while stirring. Subsequently, 10 ml of a serum-free medium is slowly added, and then centrifugation is performed. The supernatant is discarded again. The precipitated cells are suspended in a normal medium containing an appropriate amount of hypoxanthine, aminopterin, thymidine (hereinafter referred to as "HAT") solution (hereinafter referred to as "HAT medium") and human interleukin-6 (hereinafter referred to as "IL-6"), added in each well of a plate for culturing (hereinafter referred to as "plate"), and then cultured in the presence of 5% carbon dioxide gas at 37°C for approximately 2 weeks. Supplementation with a HAT medium is appropriately performed during culturing.

(5) Selection of hybridoma group

When the above myeloma cells are cells of an 8-azaguanine resistant strain, that is, the cells of a hypoxanthine guanine phosphoribosyltransferase (HGPRT)-deficient strain, unfused myeloma cells and myeloma-myeloma fusion cells are unable to survive in a HAT-containing medium. While a fusion cell of two antibody-producing cells, or a hybridoma of an antibody-producing cell and a myeloma cell can survive, the fusion cell of two antibody-producing cells has a limited life span. Thus, when culturing in a HAT-containing medium is continued, only hybridomas of antibody-producing cells and myeloma cells survive, so that the hybridoma can be selected.

For hybridomas grown to form colonies, the HAT medium is exchanged with a medium from which aminopterin has been removed (hereinafter referred to as "HT medium"). Subsequently, a part of the culture supernatant is collected, and then, for example, anti-TRAIL-R1 and R2 antibody titers are measured by the ELISA method. However, when the above fusion protein is used as an antigen for ELISA, a step of removing clones producing antibodies that specifically bind to the Fc region of human IgG is required so as not to select such a clone. The presence or absence of such a clone can be confirmed by, for example, ELISA using the Fc region of human IgG as an antigen.

The method using the 8-azaguanine resistant cell strain is as illustrated above. Other cell strains can also be used depending on a selection method for hybridomas. In this case, a medium composition to be used varies depending on the method used.

(6) Cloning step

Hybridomas that have been shown to produce specific antibodies by measuring antibody titer in a manner similar to that described in (2) are transferred to another plate and then subjected to cloning. Examples of the cloning method include the limiting dilution method wherein dilution is performed to cause each well of a plate to contain one hybridoma, followed by

culturing; the soft agar method, wherein culturing is performed in a soft agar medium and then colonies are collected; a method wherein each cell is picked with a micromanipulator and then the cell is cultured; and the sorter clone method, wherein one cell is separated with a cell sorter. The limiting dilution method is convenient, and is often used.

For the wells in which antibody titer has been detected, for example, cloning is repeated 2 to 4 times by the limiting dilution method, and then strains that have stable antibody titers are selected as anti-TRAIL-R1 and R2 monoclonal antibody-producing hybridoma strains.

In addition, a mouse-mouse hybridoma H-48-2 which is the human anti-TRAIL-R2 monoclonal antibody-producing cell of the present invention, was internationally deposited at the National Institute of Advanced Industrial Science and Technology (1-1-1, Higashi, Tsukuba, Ibaraki, Japan) on May 18, 2001. The international accession number is FERM BP-7599. In addition, a hybridoma E-11-13 was internationally deposited under the accession number of FERM BP-7698, a hybridoma F-4-8 under the accession number of FERM BP-7699, and a hybridoma L-30-10 under the accession number of FERM BP-7700 on August 8, 2001. Hence, for example, when antibodies are prepared using the mouse-mouse hybridomas, the antibodies can be prepared by step (7) and the following steps (described below) while omitting steps (1) to (6). Moreover, culturing is performed in vivo, for example, in mouse ascites, and then antibodies can be isolated from the ascites.

(7) Preparation of monoclonal antibody by culturing hybridoma

After the completion of cloning, the hybridoma is cultured in a normal medium to which HT medium is exchanged.

. Mass culture is performed by the roll-streak system using a large culture bottle, or by the spinner culture method. The supernatant in the mass culture is purified using a method known by a person skilled in the art such as gel

filtration, so that anti-TRAIL-R1 and R2 monoclonal antibodies which are contained in the prophylactic or the therapeutic agent of the present invention as an active ingredient can be obtained. Furthermore, proliferation of the hybridoma intraperitoneally in, for example, mice of the same line (e.g., BALB/c) or Nu/Nu mice, rats, guinea pigs, hamsters or rabbits makes it possible to obtain ascites containing a large amount of anti-TRAIL-R1 and R2 monoclonal antibodies which are contained in the prophylactic or the therapeutic agent of the present invention as an active ingredient. As a convenient purification method, for example, a commercially available monoclonal antibody purification kit (e.g., MAbTrap GII kit; Amersham Pharmacia Biotech) can also be used.

Monoclonal antibodies thus obtained have high antigen specificity against the human TRAIL-R1 and R2.

(8) Verification of monoclonal antibody

The isotype and the subclass of the thus-obtained monoclonal antibody can be determined as follows. Examples of identification method include the Ouchterlony method, the ELISA method and the RIA method. Although the Ouchterlony method is convenient, an enrichment step is required when the concentration of monoclonal antibodies is low.

In contrast, when the ELISA method or the RIA method is used, the culture supernatant is allowed to react intact with an antigen-coated solid phase. By further using antibodies to various immunoglobulin isotypes and subclasses as secondary antibodies, the isotype and the subclass of the monoclonal antibody can be identified.

Furthermore, protein quantification can be performed by the Folin-Lowry method, and a calculation method using absorbance at 280 nm [$1.4(\text{OD}_{280}) = \text{immunoglobulin 1 mg/ml}$].

Epitopes to be recognized by monoclonal antibodies can be identified as

follows. First, various partial structures of a molecule that the monoclonal antibody recognizes are prepared. To prepare the partial structures, for example, there exist a method whereby various partial peptides of the molecule are produced using a known oligopeptide synthesis technique and a method whereby DNA sequences encoding target partial peptides are integrated into appropriate expression plasmids using genetic engineering techniques, and then the peptides are produced inside and outside a host such as *Escherichia coli*. In general, both methods are used in combination for the above purpose. For example, a series of polypeptides are prepared to be appropriately shorter in length sequentially from the C-terminus or the N-terminus of an antigen protein, using a genetic engineering technique known to a person skilled in the art. Then, the reactivities of the monoclonal antibody against them are studied, so that the approximate recognition site is determined.

Next, more specifically, various oligopeptides corresponding to the site, mutants or the like of the peptides are synthesized using an oligopeptide synthesis technique known to a person skilled in the art. Then, the ability of the monoclonal antibody (contained as an active ingredient in the prophylactic or the therapeutic agent of the present invention) to bind to these peptides is examined, or the activity of competitive inhibition of the peptide on the binding of the monoclonal antibody with the antigen is examined, thereby specifying the epitope. As a convenient method for obtaining various oligopeptides, a commercially available kit (e.g., SPOTs kit, GENOSYS BIOTECHNOLOGIES), a kit for a series of multipin peptide synthesis (Chiron) using the multipin syntheses method or the like can also be used.

Moreover, a gene encoding a human monoclonal antibody is cloned from an antibody-producing cell such as a hybridoma, the gene is integrated into an appropriate vector, and then the vector is introduced into a host (e.g., a mammalian cell line, *Escherichia coli*, yeast cells, insect cells or plant cells). Thus, recombinant antibodies that are produced using the gene recombinant

technique can be prepared (P. J. Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P. Shepherd and C. Dean., Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS, J. W. Goding., Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).

A method employed to prepare a gene encoding a monoclonal antibody from a hybridoma comprises the step of preparing by the PCR method and the like DNAs respectively encoding the light chain variable region, light chain constant region, heavy chain variable region and heavy chain constant region of the monoclonal antibody. In this case, oligo DNAs designed from the anti-TRAIL-R antibody gene or amino acid sequence can be used as primers, and DNA prepared from the hybridoma can be used as a template. These DNAs are integrated into an appropriate vector, and then the vector is introduced into a host for expression. Alternatively, these DNAs are separately integrated into appropriate vectors, thereby causing co-expression.

Examples of vectors used herein include phages or plasmids that can autonomously grow in a host microorganism. Examples of the plasmid DNA include plasmids derived from *Escherichia coli*, *Bacillus subtilis* or yeast. An example of the phage DNA is a λ phage.

Examples of the host used for transformation are not specifically limited, as long as it can express a target gene, and include bacteria (e.g., *Escherichia coli* and *Bacillus subtilis*), yeast, animal cells (e.g., COS cells and CHO cells) and insect cells.

Methods for introducing a gene into a host are known, and any such method may be used (e.g., a method using calcium ion, the electroporation method, the spheroplast method, the lithium acetate method, the calcium phosphate method and the lipofection method). In addition, examples of a method for introducing a gene into an animal (described later) include the microinjection method, a method for introducing a gene into ES cells by the electroporation or the lipofection method, and the nucleus transplantation

method.

In the present invention, anti-TRAIL-R antibodies can be obtained by culturing transformants and collecting the antibodies from the culture product. The term "culture product" means any of (a) a culture supernatant, (b) cultured cells or cultured microbes or the disrupted cells or microbes thereof, or (c) the secretion product of the transformant. To culture transformants, a medium appropriate for the host used herein is used, and the static culture method, a culture method using a roller bottle or the like is employed.

After culturing, when a target protein is produced within microbes or cells, antibodies are collected by disrupting the microbes or the cells. Furthermore, when a target antibody is produced outside the microbes or the cells, the culture solution is used intact, or the microbes or cells are removed by centrifugation or the like. Subsequently, a target antibody can be isolated and purified from the above culture product using one of or an appropriate combination of general biochemical methods with various chromatographies that are used for protein isolation and purification.

Moreover, by the use of transgenic animal generation techniques, animal hosts having the gene of a target antibody integrated in the endogenous gene are generated, such as transgenic cattle, transgenic goats, transgenic sheep or transgenic pigs. The antibody gene-derived monoclonal antibodies can then be obtained in large quantities from the milk to be secreted from the transgenic animal (Wright, G., et al. (1991) Bio/Technology 9, 830-834). Hybridomas can be cultured in vitro using a known nutrition medium, which is used to allow the proliferation, maintenance, and storage of the hybridoma so as to cause the hybridoma to produce monoclonal antibodies in the culture supernatant depending on various conditions such as the characteristics of a cell type to be cultured, the purpose of an experiment or study, and a culture method; or any nutrition medium, which is induced and prepared from a known basic medium.

(9) Characteristics of antibody

The antibody of the present invention has the following functional properties (a) to (c), and each of the properties can be confirmed by, for example, the method described for each of (a) to (c).

- (a) When human carcinoma cells are cultured, the antibody of the present invention is contained in the medium, and the survival rate of the cells is examined, the antibody has activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or R2.
- (b) When normal human tissue-derived cells are cultured, the antibody of the present invention is contained in the medium, and the survival rate of the cells is examined, the antibody does not have effect on normal cells expressing TRAIL-R1 and/or R2.
- (c) When human hepatocytes are cultured, the antibody of the present invention is contained in the medium, and the survival rate of the cells is examined, the antibody does not induce hepatocyte toxicity.

The apoptosis-inducing activity of the antibody of the present invention can be expressed using an LD50 value (an antibody concentration, which causes death in half of the cells under a given experimental condition) as an indicator. The LD50 value is 100 $\mu\text{g}/\text{ml}$ or less, preferably 10 $\mu\text{g}/\text{ml}$ or less, more preferably 0.7 $\mu\text{g}/\text{ml}$ or less, further preferably 0.02 to 0.11 $\mu\text{g}/\text{ml}$, or most preferably 0.02 $\mu\text{g}/\text{ml}$ or less in the experimental conditions described hereinafter.

Furthermore, the term "does not have effect on normal cells" or "does not induce hepatocyte toxicity" means that the apoptosis-inducing activity of the antibody of the present invention on normal cells (human hepatocytes) is not significantly high. When an LD50 value is used as an indicator, it is 0.01 $\mu\text{g}/\text{ml}$ or more, preferably 0.1 $\mu\text{g}/\text{ml}$ or more, more preferably 2 to 10 $\mu\text{g}/\text{ml}$, further preferably 10 to 24 $\mu\text{g}/\text{ml}$ or most preferably 24 $\mu\text{g}/\text{ml}$ or more in the experimental conditions described hereinafter.

The antibody of the present invention has any of the above activities (a) to (c). The antibody is a substance having novel characteristics in that it preferably has the above activity (a) of inducing apoptosis in carcinoma cells, and the above activities (b) and (c) of not inducing damage on normal cells, particularly normal hepatocytes. Therefore, the antibody of the present invention is useful as an ingredient to be contained in a prophylactic or therapeutic agent against malignant tumors.

In the population of the antibodies which bind to TRAIL-R2 and induce apoptosis on cancer cells, there are antibodies having the character that it does not enhance the activity of inducing apoptosis on cancer cells in coexistence with TRAIL.

To the contrary, in the population of the antibodies which bind to TRAIL-R2, there are antibodies which have the activity of inducing apoptosis (including the activity of enhancing apoptosis) in coexistence with TRAIL.

Apoptosis-inducing activity on normal cells or carcinoma cells can be expressed using an LD50 value as an indicator. The LD50 value in the present invention can be calculated as follows. Normal cells (e.g., human hepatocytes) or carcinoma cells (e.g., human colon cancer cell line Colo205; ATCC CCL-222) are cultured, and then the antibody of the present invention is added to a medium. After a certain period of time, the survival rate of the cells is measured by MTT assay (Green, L. M. et al., *J. Immunological Methods*, 70: 257-268 (1984)), LDH assay or the like.

Based on a graph on which the survival rate and the concentration of the antibody added are plotted, an antibody concentration corresponding to a survival rate of 50% is determined as an LD50 value.

The LD50 value can be read from a graph, or calculated by finding a formula for a graph curve by regression calculation.

In an experiment for carcinoma cells (Colo205), 2.5×10^3 cells are seeded in 100 μ l of a medium per well of a 96-well flat-bottomed plate, and then

cultured at 37°C in the presence of 5% CO₂. On the next day, the antibodies are added, the mixture is allowed to stand for 48 hours in the above environment, and then the survival rate of the cells is measured. In the present invention, the above conditions are described as "number of cells: 2.5×10³ and reaction time: 48 hours."

In an experiment for normal cells (hepatocytes), 7.5×10⁴ cells are seeded in 100 µl of a medium per well of a 96-well flat-bottomed plate, and then cultured at 37°C in the presence of 5% CO₂. On the next day, the antibodies are added, the mixture is allowed to stand for 24 hours in the above environment, and then the survival rate of the cells is measured. In the present invention, the above conditions are described as "number of cells: 7.5×10⁴ and reaction time: 24 hours."

The antibody of the present invention includes antibodies having a property of showing an LD50 value for normal cells (human hepatocytes) of, for example, 0.01 µg/ml (10 ng/ml) or more, or preferably 0.1 µg/ml or more when the LD50 value is measured under the above conditions. It can be said that the higher the LD50 value against normal cells, the higher the safety. Thus, antibodies having LD50 values of 2 to 100 µg/ml are further preferred. The antibody of the present invention includes antibodies having a property of showing the LD50 value for carcinoma cells of, for example, 100 µg/ml or less, or preferably 0.7 µg/ml or less when the LD50 value is measured under the above conditions. It can be said that lower the LD50 value against carcinoma cells, the stronger the activity to kill tumor cells. Thus, antibodies having LD50 values of 0.02 to 0.11 µg/ml are further preferred. In particular, the E-11-13 antibody, the L-30-10 antibody of the present invention have properties of showing LD50 values for human hepatocytes of 2 to 100 µg/ml or more (for example, 2 to 24 µg/ml, preferably, 100 µg/ml) and LD50 values for carcinoma cells of 0.02 to 0.11 µg/ml. That is, these antibodies have both safety for normal cells and an apoptosis-inducing effect on tumor cells. Furthermore

surprisingly, the antibody of the present invention significantly suppressed tumor cell proliferation in a tumor-bearing mouse model.

The ratio of the LD50 value for normal cells measured under conditions where "number of cells: 7.5×10^4 and reaction time: 24 hours" to the LD50 value for carcinoma cells measured under conditions where "number of cells: 2.5×10^3 and reaction time: 48 hours" is next examined. As described above, the higher the LD50 value for normal cells, the higher the safety, and the lower the LD50 value for carcinoma cells, the stronger the activity to kill tumor cells. Hence, antibodies having a higher ratio of the LD50 value for normal cells to that for carcinoma cells can be said to be useful (higher safety and stronger apoptosis-inducing activity in carcinoma cells). The ratio of the LD50 value for carcinoma cells to that for normal cells (showing how many times the LD50 value for normal cells is greater than that for carcinoma cells) is supposed to be an N/C ratio. The antibody of the present invention has a property of having N/C=2 or more, namely, having a LD50 value for normal cells which is twice or more greater than that for carcinoma cells. Preferably the LD50 for normal cells is 10 times or more greater (N/C=10 or more) than that for carcinoma cells, more preferably, N/C=10 to 25. Hereinafter, the N/C ratio, in order of preference, is as follows: N/C=50, N/C=50 or more, N/C=50 to 100, and still preferably N/C=100 to 240 and most preferably N/C=240 or more.

Pharmaceutical composition

A preparation containing a preparation that is prepared by purifying the human anti-TRAIL-R1 and R2 antibodies of the present invention is also encompassed within the scope of the present invention. Such a preparation preferably contains a physiologically acceptable diluent or carrier in addition to the antibody, and may be a mixture with other antibodies or other drugs such as antibiotics. Examples of an appropriate carrier include, but are not limited to, a physiological saline solution, a phosphate buffered saline solution, a

phosphate buffered saline glucose solution and a buffered physiological saline. Alternatively, the antibody may be freeze-dried, and then used when necessary by adding the above buffered aqueous solution for reconstitution. The prophylactic or therapeutic agent can be administered in various forms. Examples of the forms of administration of these agents include oral administration using vehicles such as tablets, capsules, granules, powders or syrups, and parenteral administration using vehicles such as injections, drops or suppositories.

The dose differs depending on symptom, age, body weight and the like. Normally in the case of oral administration, the dose is approximately 0.01 mg to 1000 mg per day for an adult, and it can be administered once or separately administered on several different occasions. Further, in the case of parenteral administration, a dose of approximately 0.01 mg to 1000 mg per administration can be administered by subcutaneous injection, intramuscular injection or intravenous injection.

The antibody or the pharmaceutical composition of the present invention can be applied to treatment of or prophylaxis against various diseases or symptoms that may be caused by cells expressing TRAIL-R1 and R2. Examples of such diseases or the symptoms include various malignant tumors.

Examples of the types of such tumors include colon cancer, colorectal cancer, lung cancer, breast cancer, brain tumor, malignant melanoma, renal cell carcinoma, leukemia, lymphomas, T cell lymphomas, gastric cancer, pancreas cancer, cervical cancer, endometrial carcinoma, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, cutaneous cancer, urinary tract carcinoma, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecomatosis, androblastoma, endometrium hyperplasy, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, angioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendrolioma, medulloblastoma, ganglioneuroblastoma,

glioma, rhabdomyosarcoma, hamartoblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma and Wilms tumor. The number of the types of tumors to which the antibody of the present invention is applied is not limited to one type, and plural types of tumors may develop at the same time.

Example of preparation

The molecule of the present invention is used in the form of an ampule of aseptic solution or suspension prepared by dissolving the molecule in water or a pharmacologically acceptable solution other than water. In addition, an ampule may be filled with an aseptic powder preparation (preferably, where the molecule of the present invention is freeze-dried), and it can be diluted with a pharmacologically acceptable solution when used.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the cell-death-inducing activity on Colo205 in the culture supernatant of hybridomas producing human anti-TRAIL-R1 monoclonal antibodies.

Figure 2 shows the cell-death-inducing activity on Colo205 in the culture supernatant of hybridomas producing human anti-TRAIL-R2 monoclonal antibodies.

Figure 3 shows the cell-death-inducing activity on Colo205 in the culture supernatant of hybridomas producing human anti-TRAIL-R2 monoclonal antibodies (Goat anti-human IgG(γ) specific polyclonal antibodies were not present).

Figure 4 shows the cell-death-inducing activity on HUVEC in the culture supernatant of hybridomas producing human anti-TRAIL-R2 monoclonal antibodies.

Figure 5 shows the cell-death-inducing activity of purified human anti

TRAIL-R2 monoclonal antibody on Colo205 and normal human hepatocytes.

Figure 6 shows the activity of purified human anti TRAIL-R2 monoclonal antibody in coexistence of TRAIL.

Figure 7 shows the results of measuring the tumor size when purified human anti-TRAIL-R2 monoclonal antibodies E-11-13, F-4-8, H-48-2, L-30-10 and W-40-5 were administered at 1 μ g/mouse three times on alternate days.

Figure 8 shows the results of measuring the tumor size when purified human anti-TRAIL-R2 monoclonal antibodies E-11-13 were administered at 4, 20 and 100 μ g/mouse 4 times.

Figure 9 shows the results of measuring the tumor size when purified human anti-TRAIL-R2 monoclonal antibodies E-11-13 were administered at 20 μ g/300 mm³ tumor-bearing mouse three times on alternate days.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention will be described more specifically by the following examples. The present invention is not limited to the embodiments described in these examples.

Example 1 Preparation of antigen

To obtain cells excessively expressing human TRAIL-R1 and R2 on the cell membrane, plasmid vectors for the expression of human TRAIL R1 and human TRAIL-R2 (which had been prepared by removing the death domain and the amino acids on the C-terminal side from the death domain in the intracellular regions from the full-length amino acids of the human TRAIL-R1 and R2, hereinafter referred to as TRAIL-R1 and R2delta,) were prepared. DNAs encoding TRAIL-R1 and R2delta were prepared by the PCR method.

a) Construction of full-length human TRAIL-R1 and R2 expression vectors

To perform template PCR, plasmid vectors, pcDNA3-TRAIL-R1 and

pcDNA3-TRAIL-R2, retaining cDNAs encoding human TRAIL-R1 and R2 were used as templates. pcDNA3-TRAIL-R1 and pcDNA3-TRAIL-R2 were constructed by the following method. The full-length human TRAIL-R1 DNA and TRAIL-R2 DNA were modified by polymerase chain reaction (PCR) to add an *Eco*R I sequence to the 5' end, and a *Not* I sequence and a termination codon to the 3' end. Using human placenta-derived cDNA (Clontech) as a template, primers 5'-CACGAATTCAACCATGGCGCCACCACCAGCT-3' (SEQ ID NO: 1) and

5'-TTTCTCGAGGCGGCCGCTTATCACTCCAAGGACACGGCAGAGCCTGT G-3' (SEQ ID NO: 2) synthesized for TRAIL-R1, and primers 5'-CACGAATTCGCCACCATGGAACAAACGGGGACAG-3' (SEQ ID NO: 3) and

5'-TTTCTCGAGGCGGCCGCTCATTAGGACATGGCAGAGTCTGCATTACCT -3' (SEQ ID NO: 4) synthesized for TRAIL-R2, a PCR reaction was performed for 30 cycles (each cycle consisting of 94°C for 20 seconds, 60°C for 30 seconds and 68°C for 90 seconds) using platinum PfxDNA polymerase (Gibco BRL). The modified TRAIL-R1 and TRAIL-R2 sequences were isolated as *Eco*R I-*Not* I fragments, and then ligated to pcDNA3 (Invitrogen) vectors that had been cleaved with the same enzymes. The obtained plasmids were named pcDNA3-TRAIL-R1 and pcDNA3-TRAIL-R2. Of the two fragments formed by alternative splicing, TRAIL-R2 integrated in pcDNA3-TRAIL-R2 comprises 440 amino acids encoded by a 1320 bp cDNA. Hereinafter, the reaction temperature for all the PCRs in the examples was regulated using a GeneAmp PCR system 9700 (Perkin Elmer Japan).

b) Construction of human TRAIL-R1 and R2delta expression vectors

Human TRAIL-R1 and R2delta expression vectors were constructed by the following methods. To prepare an expression plasmid comprising a TRAIL-R1 partial peptide having an amino acid sequence of 1 to 351, and the

same comprising a TRAIL-R2 partial peptide having an amino acid sequence of 1 to 348, PCR reaction was performed to add an *Eco*R I sequence to the 5' ends of the TRAIL-R1 and R2 partial peptides, and an *Not* I sequence and a termination codon to the 3' ends of the same. PCR was performed for 25 cycles (each cycle consisting of 94°C for 20 seconds, 65°C for 30 seconds and 68°C for 75 seconds) using oligonucleotide primers 5'-CACGAATTCAACCATGGCGCCACCACCAGCT-3' (SEQ ID NO: 1) and 5'-TTCTACGAGCGGCTTATCACAGCCTCCTCTGAGA-3' (SEQ ID NO: 5) for TRAIL-R1, and oligonucleotide primers 5'-CACGAATTGCCACCATGGAACAAACGGGGACAG-3' (SEQ ID NO: 3) and 5'-TTCTACGAGCGGCCGCTTATCACAAAGTCTGCAAAGTCATC-3' (SEQ ID NO: 6) for TRAIL-R2, platinum PfxDNA polymerase (Gibco BRL), pcDNA3-TRAIL-R1 and pcDNA3-TRAIL-R2. The modified TRAIL-R1 and R2 partial peptides were isolated as *Eco*R I-*Not* I fragments. The *Eco*R I-*Not* I fragment was ligated to pEFneo vectors that had been cleaved with *Eco*R I and *Not* I enzymes. The obtained plasmids were named pEF-TRAIL-R1delta and pEF-TRAIL-R2delta.

c) Preparation of human TRAIL-R1 and R2delta-expressing cells

pEF-TRAIL-R1delta and pEF-TRAIL-R2delta prepared in b) were introduced into L929 cells (American Type Culture Collection No.CCL-1) using LipofectAMINE Plus (Gibco BRL). Transfection was performed by the method described in the manual. After 24 hours of culturing in a flask for culturing cells (with a culture area of 75 cm²) at 37°C under 5.0% carbon dioxide gas, G418 (Gibco BRL) was added at 1 mg/ml in the culture, followed by 1 week of culturing. Subsequently, FACS analysis was performed using goat anti-human TRAIL-R1 polyclonal antibodies and goat anti-human TRAIL-R2 polyclonal antibodies (DAKO). Thus, it was confirmed that the transfected cells, which had acquired a G418 resistance trait, expressed

TRAIL-R1delta comprising 351 amino acids and TRAIL-R2delta comprising 348 amino acids on the cell membrane surface.

The synthesis of oligonucleotides such as primers for PCR was always performed using an automated DNA synthesis system (model 3948, Perkin Elmer Japan, Applied Biosystems division) according to the manual [see Matteucci, M. D. and Caruthers, M.H. (1981) *J. Am. Chem. Soc.* 103, 3185-3191]. After the end of synthesis, each oligonucleotide was cleaved from the support and then deprotected. The obtained solution was dried and solidified, and the product was dissolved in distilled water, and then cryopreserved at -20°C until use.

Example 2 Generation of human antibody-producing mice

The mice used for immunization had a genetic background whereby they were homozygotes for both disrupted endogenous Ig heavy chain and κ light chain, and the mice harbored at the same time chromosome 14 fragment (SC20) containing a human Ig heavy chain locus, and a human Ig κ chain transgene (KCo5). These mice were generated by crossing mice of a line A having a human Ig heavy chain locus with mice of a line B having a human Ig κ chain transgene. The mice of line A are homozygotes for both disrupted endogenous Ig heavy chain and κ light chain, and harbor chromosome 14 fragment (SC20), which is transmittable to progeny, as is described, for example, in the report of Tomizuka et al. (Tomizuka. et al., *Proc Natl Acad Sci USA.*, 2000 Vol 97: 722). Furthermore, the mice of line B (transgenic mice) are homozygotes for both disrupted endogenous Ig heavy chain and κ light chain, and harbor a human Ig κ chain transgene (KCo5), as described, for example, in the report of Fishwild et al. (*Nat Biotechnol.*, 1996 Vol 14:845).

Progeny mice obtained by crossing male mice of the line A with female mice of the line B, or female mice of the line A with male mice of the line B, were analyzed by the method described in Tomizuka et al's report (Tomizuka et

al., Proc Natl Acad Sci USA., 2000 Vol 97:722). Individuals (human antibody-producing mice) having human Ig heavy chain and κ light chain detected simultaneously in the sera were screened for (Ishida & Lonberg, IBC's 11th Antibody Engineering, Abstract 2000) and used for the following immunization experiment. In addition, the above human antibody-producing mice are available from Kirin Brewery Co., Ltd via contract.

Example 3 Preparation of human monoclonal antibodies against human TRAIL-R1 and R2

In this example, monoclonal antibodies were prepared according to general methods as described in, for example, Introduction of Experimental Protocols for Monoclonal Antibody (Monoclonal Antibody Jikken Sosa Nyumon, written by Tamie ANDO et al., KODANSHA, 1991). As immunogens, the TRAIL-R1 and R2delta-expressing L929 cell prepared in Example 1 was used. Animals used for immunization were the human antibody (human immunoglobulin)-producing mice generated in Example 2.

To prepare human monoclonal antibodies against human TRAIL-R1, human antibody-producing mice were initially immunized via the right foot pad with the TRAIL-R1delta-expressing L929 cells (3×10^6 cells/mouse) prepared in Example 1. After the initial immunization, immunization with the L929 cells was performed 10 times every 3 days via the left and right foot pad alternatively. Furthermore, at 3 days before the obtainment of the spleen and the lymph node (described later), the L929 cells were used for immunization via both foot pads. To prepare human monoclonal antibodies against human TRAIL-R2, human antibody-producing mice (1×10^7 cells/mouse) were initially immunized intraperitoneally with the TRAIL-R2delta-expressing L929 cells prepared in Example 1. After the initial immunization, immunization with the L929 cells was performed 5 times a week intraperitoneally. Furthermore, at 3 days before the obtainment of the spleen (described later) the L929 cells were used for

immunization via the caudal vein.

The spleens and/or the lymph nodes were obtained by a surgical operation from the immunized mice. Then the organ was put into 10 ml of a serum-free DMEM medium (Gibco BRL) containing 350 mg/ml sodium hydrogen carbonate, 50 units/ml penicillin and 50 μ g/ml streptomycin (hereinafter, referred to as "serum-free DMEM medium"). It was then pulverized using a spatula on mesh (Cell strainer: Falcon). The cell suspension that had passed through the mesh was centrifuged so as to precipitate the cells. The cells were washed twice in a serum-free DMEM medium, and suspended in a serum-free DMEM medium, and then the number of the cells was counted. In the meantime, myeloma cells SP2/0 (ATCC No. CRL-1581) that had been cultured so as not to exceed a cell concentration of 1×10^8 cells/ml at 37°C in the presence of 5% carbon dioxide gas in a 10% FCS (Sigma)-containing DMEM medium (Gibco BRL) (hereinafter referred to as "serum-containing DMEM medium") were washed in a serum-free DMEM medium in the same manner. Then the cells were suspended in a serum-free DMEM medium, and then the number of the cells was counted. The collected cell suspension and the mouse myeloma suspension were mixed at a cell number ratio of 5:1. The mixture was centrifuged, thereby completely removing the supernatant. To this pellet, 1 ml of 50% (w/v) polyethylene glycol 1500 (Boehringer Mannheim) was gently added as a fusion agent while agitating the pellet using the tip of a pipette. Next, 1 ml of a serum-free DMEM medium preheated at 37°C was gently added at two separate times, followed by addition of another 7 ml of serum-free DMEM medium. After centrifugation, the fusion cells obtained by the removal of the supernatant were subjected to screening by the limiting dilution method described below. Screening for hybridomas was performed by culturing the cells in DMEM media containing 10% fetal calf serum (FCS), hypoxanthine (H), aminopterin (A) and thymidine (T) (hereinafter referred to as "HAT": Sigma). Further, single clones were obtained using DMEM media containing HT (Sigma)

by the limiting dilution method. Culturing was performed in a 96-well microtiter plate (Beckton Dickinson). Screening for hybridoma clones producing anti-human TRAIL-R1 and R2 human monoclonal antibodies and characterization of the human monoclonal antibodies produced by each of the hybridomas were performed by the enzyme-linked immunosorbent assay (ELISA) and fluorescence activated cell sorter (FACS) described below.

For the screening of human monoclonal antibody producing cells hybridoma by ELISA, by ELISA described in Examples 4 and 5 and the FACS analysis described in Example 6, a large number of hybridomas producing human monoclonal antibodies that have human immunoglobulin γ chain (hIg γ) and human immunoglobulin light chain κ , and have reactivity specifically to human TRAIL-R1 and/or R2 were obtained. Furthermore, in any of the following examples including this example, and tables and figures showing the test results of the examples, hybridoma clones producing each of the human anti-human TRAIL-R1 and R2 monoclonal antibodies of the present invention were denoted using symbols. The following hybridoma clones represent single clones: 1-13, 1-18, 1-32, 1-40, 1-43, 2-6, 2-11, 2-12, 2-18, 2-47, 2-52, 3-1, 3-7, 3-10, 3-23, 3-33, 3-42, 3-53, 1-13-6, 1-32-9, 1-40-4, 1-43-43, 2-6-48, 2-11-5, 2-12-10, 2-47-11, 2-52-12, 3-10-19, 3-23-8, 3-33-7, 3-42-3, 3-53-15, 2-18-2, 3-1-7, E-11, E-14, L-30, N-18, X-14, E-11-13, E-14-4, F-4-2, F-4-8, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-4, X-51-12, A-11, G-3, H-34, I-22, I-35, J-21, J-26, K-8, K-16, K-57, L-4, P-28, P-36, W-42, X-13, X-60, Z-23, 1-39, A-4-27, A-4-29, G-3-10, H-34-2, K-57-12 and W-42-2. H-48-2 of these clones was internationally deposited at the National Institute of Advanced Industrial Science and Technology (1-1-1, Higashi, Tsukuba, Ibaraki, Japan) on May 18, 2001. The international accession number is FERM BP-7599. Furthermore, E-11-13, F-4-8 and L-30-10 were internationally deposited with the above deposition center on August 8, 2001. The international accession number of

E-11-13 is FERM BP-7698, that of F-4-8 is FERM BP-7699, and that of L-30-10 is FERM BP-7700. Furthermore, E-11-13, F-4-8 and L-30-10 were internationally deposited with the above deposition center on October 11, 2001. The international accession number of E-11-13 is FERM BP-7770, that of F-4-8 is FERM BP-7768, and that of L-30-10 is FERM BP-7769.

Example 4 Detection of human anti-TRAIL-R1 monoclonal antibody or human anti-TRAIL-R2 monoclonal antibody having human immunoglobulin light chain κ (Ig κ)

Fusion proteins of the extracellular regions of human TRAIL-R1 and R2 and the Fc region of human IgG1 (hereinafter referred to as "TRAIL-R1-hFc" and "TRAIL-R2-hFc" (ALEXIS)) were added at 0.5 μ g/ml in phosphate buffered saline (hereinafter referred to as "PBS"). 50 μ l of the thus prepared solution was added to each well of a 96-well microplate for ELISA (Maxisorp, Nunc) and incubated for 1 hour at room temperature, thereby coating TRAIL-R1-hFc or TRAIL-R2-hFc to the microplate. Subsequently the supernatant was discarded, a blocking reagent (SuperBlock (registered trademark) Blocking Buffer, PIERCE) was added to each well, and then incubation was performed at room temperature for 30 minutes, thereby blocking the part where TRAIL-R1-hFc or TRAIL-R2-hFc did not bind. Thus, a microplate having each well coated with TRAIL-R1-hFc or TRAIL-R2-hFc was prepared.

The culture supernatant of each hybridoma (50 μ l) was added to each well, reaction was performed at room temperature for 1 hour, and then each well was washed twice in 0.1% Tween20-containing PBS (PBS-T). Subsequently, horseradish peroxidase-labeled goat anti-human Ig κ antibodies (50 μ l/well, Biosource International) were diluted 2000 times in PBS-T containing 10% Block Ace (Dainippon Pharmaceutical Co., Ltd.). 50 μ l of the thus prepared solution was added to each well, and incubation was then performed at room temperature for 30 minutes. The microplate was washed three times with

PBS-T, and then 100 μ l of a TMB chromogenic substrate solution (DAKO) was added to each well, followed by incubation at room temperature for 20 minutes. 0.5M sulfuric acid was added (100 μ l/well) to each well to stop reaction. Absorbance at a wavelength of 450 nm (reference wavelength of 570 nm) was measured with a microplate reader (MTP-300, Corona Electric).

Table 1 and Table 2 show the characteristics of the part of antibodies among the thus obtained anti-human TRAIL-R1 and R2 antibodies. Table 1 shows the subclass and cross reactivity of the obtained human anti-TRAIL-R1 monoclonal antibodies. Table 2 shows the subclass and cross reactivity of the obtained human anti-TRAIL-R2 monoclonal antibodies.

Table 1

Human anti-TRAIL-R1 antibody	Subclass	Cross reactivity	
		TRAIL-R1	TRAIL-R2
1-13	IgG4	+	—
1-18	IgG4	+	—
1-32	IgG1	+	—
1-40	IgG1	+	—
1-43	IgG1	+	—
2-6	IgG1	+	—
2-11	IgG1	+	—
2-12	IgG1	+	—
2-18	IgM	+	—
2-47	IgG4	+	—
2-52	IgG1	+	—
3-1	IgM	+	—
3-7	IgM	+	—
3-10	IgG4	+	—
3-23	IgG4	+	—
3-33	IgG4	+	—
3-42	IgG2	+	—
3-53	IgG1	+	—

+ : with reactivity

— : no reactivity

Table 2

Human anti-TRAIL-R2 antibody	Subclass	Cross reactivity	
		TRAIL-R1	TRAIL-R2
A-4-27	IgM	—	+
A-4-29	IgM	+	+
A-11	IgM	—	+
E-11	IgG1	—	+
E-14	IgG1	—	+
F-4-2	IgG4	—	+
F-4-8	IgG1	—	+
G-3	IgM	—	+
H-34	IgM	—	+
H-48-2	IgG1	—	+
I-22	IgM	—	+
I-35	IgM	—	+
J-21	IgM	—	+
J-26	IgM	—	+
K-8	IgM	—	+
K-16	IgM	—	+
K-57	IgM	—	+
L-4	IgM	—	+
L-30	IgG1	—	+
N-18	IgG4	—	+
P-28	IgM	—	+
P-36	IgM	—	+
W-40-5	IgG1	—	+
W-42	IgM	—	+
X-13	IgM	—	+

X-14	IgG4	—	+
X-51-4	IgG1	—	+
X-51-12	IgG4	—	+
X-60	IgM	—	+
Z-23	IgM	—	+
1-39	IgM	—	+

+ : with reactivity

— : no reactivity

Example 5 Identification of the subclass of each monoclonal antibody

A microplate having each well coated with TRAIL-R1-hFc or TRAIL-R2-hFc was prepared by a method similar to that of Example 4, and then each well was washed twice with PBS-T. The culture supernatant (50 μ l) of each of the hybridomas obtained in Example 4 was added to each well of the microplate coated with TRAIL-R1-hFc or TRAIL-R2-hFc to perform reaction for 1 hour, and then each well was washed twice with PBS-T. Subsequently, sheep anti-human IgG1 antibodies, sheep anti-human IgG2 antibodies, or sheep anti-human IgG3 antibodies or sheep anti-human IgG4 antibodies, which had been respectively labeled with horseradish peroxidase and diluted 2000 times, were added (50 μ l/well, The Binding Site) to each well, followed by incubation at room temperature for 1 hour. After washing 3 times with PBS-T, a substrate buffer (TMB, 100 μ l/well, DAKO) was added to each well, and then incubation was performed at room temperature for 20 minutes. Next, 0.5M sulfuric acid (100 μ l/well) was added to stop the reaction. Absorbance at a wave length of 450 nm (with a reference wavelength of 570 nm) was measured using a microplate reader (MTP-300, Corona Electric). The above Table 1 and Table 2 show the results.

Example 6 Test of the reactivity of each monoclonal antibody to TRAIL-R1 and R2 expressing cells

The reactivity of each of the monoclonal antibodies obtained in Example 4 to the TRAIL-R1delta-expressing L929 cells and TRAIL-R2delta-expressing L929 cells prepared in Example 1 was examined by FACS analysis. L929 cells, TRAIL-R1delta-expressing L929 cells and TRAIL-R2delta-expressing L929 cells were suspended at a concentration of 2×10^6 /ml in a staining buffer (SB) of PBS containing 1% rabbit serum, 0.1% NaN_3 and 1% FCS. The cell suspension (100 μ l/well) was added into a 96-well round-bottomed plate (Beckton Dickinson). After centrifugation (2000 rpm, 4°C, 2 minutes), the

supernatant was removed and then the culture supernatant (50 μ l) of the hybridoma cultured in Example 3 was added. The mixture was agitated, allowed to stand on ice for 30 minutes, and then subjected to centrifugation (2000 rpm, 4°C for 2 minutes) to remove the supernatant. After the pellet was washed twice with SB (100 μ l/well), 30 μ l of 0.0125 mg/ml RPE fluorescence-labeled rabbit anti-human Ig κ F(ab')₂ antibodies (DAKO) was added, and then incubation was performed on ice for 30 minutes. After washed twice with SB, the cells were suspended in 300 μ l of SB, and then fluorescence intensity of each cell was measured by FACS (FACScan, Beckton Dickinson). As a result, all the antibodies were observed to have strong binding activity only to the TRAIL-R1delta-expressing L929 cells or the TRAIL-R2delta-expressing L929 cells, and no binding activity to L929 cells was observed. Thus, it was shown that they were antibodies binding specifically to TRAIL-R1 and TRAIL-R2.

Example 7 Cell-death-inducing activity on carcinoma cells

Using the culture supernatant of the hybridoma producing the human anti-TRAIL-R1 monoclonal antibodies or the human anti-TRAIL-R2 monoclonal antibodies obtained from Example 4 to 6, cell-death-inducing activity on Colo205 (ATCC No. CCL-222) cells, which were colon carcinoma cells, was measured. Colo205 cells cultured in RPMI media containing 10% FCS were prepared at a concentration of 2.5×10^4 /ml. 100 μ l of the suspension was added to each well of a 96-well flat bottomed plate (Beckton Dickinson). After culturing at 37°C under 5.0% carbon dioxide gas for 24 hours, the hybridoma culture supernatant was added at 50 μ l/well. Furthermore, when the human anti-TRAIL-R1 monoclonal antibody or the human anti-TRAIL-R2 monoclonal antibody was IgG, goat anti-human IgG (γ)-specific polyclonal antibodies (Sigma) were added (10 μ l/well) to each well at a final concentration of 5 μ g/ml. For a part of the obtained hybridomas, wells not supplemented

with goat anti-human IgG (γ)-specific polyclonal antibodies were prepared. As a positive control, human recombinant TRAIL protein (DAKO) was employed with a final concentration of 100 ng/ml. As a negative control, human IgG (Biogenesis) was employed. After 48 hours of culturing at 37°C under 5.0% carbon dioxide gas, an MTS reagent (Cell Titer 96 AQUEOUS Non-Radioactive Cell Proliferation Assay: Promega) was prepared according to the method described in the instructions, and then 20 μ l of the reagent was added to each well. After another 2 hours of culturing at 37°C under 5.0% carbon dioxide gas, absorbance at a wavelength of 490 nm (reference wavelength of 630 nm) was measured using a microplate reader (1420 ARVO multi-label counter: WALLAC). Using the reducibility of mitochondria as an indicator, the survival rate of the cells was calculated. The survival rate of the cells in each well was calculated by the following formula: Survival rate (%) = $100 \times (a-b)/(c-b)$ (wherein "a" represents the measured value of a well tested, "b" represents the measured value of a cell-free well, and "c" represents the measured value of a negative control well). Figures 1 to 3 and Tables 3 and 4 show the results. Table 3 shows the cell-death-inducing activity (in the culture supernatant of the hybridomas producing the human anti-TRAIL-R1 monoclonal antibodies) on Colo205 and normal human hepatocytes. Table 4 shows the cell-death-inducing activity (in the culture supernatant of the hybridomas producing the human anti-TRAIL-R2 monoclonal antibodies) on Colo205 and human normal hepatocytes.

Table 3

Human anti-TRAIL-R1 antibody	Subclass	Normal human hepatocyte survival rate	Colo205 cell survival rate
1-13-6	IgG4	—	—

1-32-9	IgG1	—	—
1-40-4	IgG1	—	—
1-43-43	IgG1	—	—
2-6-48	IgG1	—	—
2-11-5	IgG1	++	++
2-12-10	IgG1	—	—
2-47-11	IgG4	+	+
2-52-12	IgG1	++	++
3-10-19	IgG4	—	—
3-23-8	IgG4	—	—
3-33-7	IgG4	—	—
3-42-3	IgG2	—	—
3-53-15	IgG1	—	—
2-18-2	IgM	++	++
3-1-7	IgM	—	+
sTRAIL 1 µg/ml	-	—	—

++: Survival rate of 80% or more

+: Survival rate of 21% to 79%

-: Survival rate of 20% or less

Table 4

Human anti-TRAIL-R2 antibody	Subclass	Normal human hepatocyte survival rate	Colo205 cell survival rate
E-11-13	IgG1	++	-
E-14-4	IgG1	+	+
F-4-2	IgG4	+	-
F-4-8	IgG1	-	-
H-48-2	IgG1	++	-
L-30-10	IgG1	++	-
N-18-12	IgG4	++	-
W-40-5	IgG1	++	+
X-14-4	IgG4	++	+
W-51-4	IgG1	-	-
X-51-12	IgG4	++	-
A-4-29	IgM	-	-
G-3-10	IgM	++	-
H-34-2	IgM	-	-
K-57-12	IgM	+	-
W-42-2	IgM	-	-
sTRAIL 1 µg/ml	-	-	-

++: Survival rate of 80% or more

+: Survival rate of 21% to 79%

- : Survival rate of 20% or less

As a result, it was revealed that the human anti-TRAIL-R1 and R2 monoclonal antibodies clearly had activity to induce cell death in Colo205 cells, compared with the negative control. Moreover, it was shown that a part of the human anti-TRAIL-R2 monoclonal antibodies, which is IgG, had activity to

induce cell death even in the absence of goat anti-human IgG(γ)-specific polyclonal antibodies (in a state without cross-linking with the human anti-TRAIL-R2 monoclonal antibodies).

Example 8 Cell-death-inducing activity on normal cells

Cell-death-inducing activity on HUVEC (Biowhittaker), which is a normal human umbilical vein endothelial cell, was measured using the culture supernatant of the hybridomas producing the human anti-TRAIL-R2 monoclonal antibodies obtained in Examples 4 to 6. HUVEC cells cultured in an EGM-2 medium (Biowhittaker) were prepared at a concentration of 5×10^4 /ml. 100 μ l of the suspension was added to each well of a 96-well flat-bottomed plate (Beckton Dickinson). The cells were cultured at 37°C under 5.0% carbon dioxide gas for 24 hours, and then the culture supernatant of the hybridoma was added at 50 μ l/well. Further, when the human anti-TRAIL-R1 monoclonal antibody or the human anti-TRAIL-R2 monoclonal antibody was IgG, 10 μ l of goat anti-human IgG(γ)-specific polyclonal antibodies (Sigma) were added at a final concentration of 5 μ g/ml to each well. Human IgG (Biogenesis) was used as a negative control. After 48 hours of culturing at 37°C under 5.0% carbon dioxide gas, an MTS reagent (Cell Titer 96 AQUEOUS Non-Radioactive Cell Proliferation Assay: Promega) was prepared according to the method described in the instructions, and then 20 μ l of the reagent was added to each well. After another 2 hours of culturing at 37°C under 5.0% carbon dioxide gas, absorbance at a wavelength of 490 nm (with a reference wavelength of 630 nm) was measured using a microplate reader (1420 ARVO multi-label counter: WALLAC). Using the reducibility of mitochondria as an indicator, the survival rate of the cells was calculated. The survival rate of the cells of each well was calculated by a formula similar to that of Example 7.

Figure 4 shows the result. The human anti-TRAIL-R2 monoclonal antibody and the negative control showed almost the same result, revealing that

the human anti-TRAIL-R2 monoclonal antibody does not show cytotoxicity against HUVEC cells.

Example 9 Cell-death-inducing activity on normal human hepatocytes

Cell-death-inducing activity on normal human hepatocytes (hereinafter referred to as "HH cells") (Tissue Transformation Technologies) was measured using the culture supernatant of the hybridomas producing the human anti-TRAIL-R1 and R2 monoclonal antibodies obtained in Examples 4 to 6. First, frozen HH cells were thawed at 37°C, and then prepared at a concentration of 7.5×10^5 /ml using a CM5300 medium (CEDRA). 100 μ l of the suspension was added to each well of a 96-well flat-bottomed plate coated with collagen type I (Beckton Dickinson). After 4.5 hours of culturing at 37°C under 5.0% carbon dioxide gas, medium exchange was performed. After 24 hours of culturing at 37°C under 5.0% carbon dioxide gas, medium exchange was performed again. Subsequently, the culture supernatant of the hybridoma was added at 50 μ l/well, and then 10 μ l of goat anti-human IgG(γ)-specific polyclonal antibodies (Sigma) were added to each well at a final concentration of 5 μ g/ml. Human IgG (Biogenesis) was used as a negative control. After 24 hours of culturing at 37°C under 5.0% carbon dioxide gas, morphological changes in HH cells were observed under a microscope. The result of the human anti-TRAIL-R2 monoclonal antibody and that of negative control were almost the same, revealing that the human anti-TRAIL-R2 monoclonal antibody does not show cytotoxicity also against HH cells.

Example 10 Preparation of each antibody

The human anti-TRAIL-R2 monoclonal antibodies from the culture supernatant of the hybridomas obtained from Examples 4 to 6 were purified by the following method. The culture supernatant containing the human anti-TRAIL-R2 monoclonal antibodies was subjected to affinity purification

using rmp Protein A (Amersham Pharmacia Biotech), a 0.8×40 cm column (Bio-Rad), PBS as an adsorption buffer and a 0.02 M glycine buffer (pH 3) as an elution buffer. The eluted fraction was adjusted to have a pH of around 7.2 by adding 1 M Tris (pH 9.0). The thus prepared antibody solution was substituted with PBS using a dialysis membrane (10000 cut, Spectrum Laboratories), and then filtered using a MILLEX-GV membrane filter (Millipore) with a pore size of 0.22 μ m for sterilization, thereby obtaining purified human anti-TRAIL- R2 monoclonal antibodies. Absorbance at 280 nm was measured, and then the concentration of the purified antibodies was calculated using 1.4 OD = 1mg/ml.

The culture supernatant containing the human anti-TRAIL- R2 monoclonal antibodies was prepared by the following method. First, human anti-TRAIL-R2 monoclonal antibodies-producing hybridomas were adapted in an eRDF medium (Kyokutoseiyaku) containing 10 ng/ml Recombinant Human IL-6 (R&D Systems) and 10% Low IgG fetal bovine serum (HyClone). The adapted hybridomas were cryopreserved. Next, for the purpose of antibody purification, a part of the hybridomas was adapted in an eRDF medium (Kyokutoseiyaku) containing bovine insulin (5 μ g/ml, Gibco BRL), human transferrin (5 μ g/ml, Gibco BRL), ethanolamine (0.01 mM, Sigma), sodium selenite (2.5×10^{-5} mM, Sigma), 10 ng/ml recombinant human IL-6 (R&D Systems) and 1% Low IgG fetal bovine serum (HyClone). The hybridoma cells were cultured in flasks, and when the viable cell ratio of the hybridoma reached 90%, the culture supernatant was collected. The collected supernatant was applied to a 10 μ m filter and a 0.2 μ m filter (German Science), thereby removing miscellaneous waste materials such as hybridomas.

Example 11 Cell-death-inducing activity of purified human anti-TRAIL-R2 monoclonal antibody on carcinoma cells and normal human hepatocytes

The cell-death-inducing activity on the colon carcinoma cell Colo205 (ATCC No. CCL-222) was measured using the purified human anti-TRAIL-R2

monoclonal antibodies obtained in Example 10. Colo205 cells cultured in RPMI media containing 10% FCS were prepared at a concentration of 2.5×10^4 /ml, and then the 100 μ l of the suspension was added to each well of a 96-well flat-bottomed plate (Beckton Dickinson). After 24 hours of culturing at 37°C under 5.0% carbon dioxide gas, the purified antibodies were added (10 μ l/well) at final concentrations of 10, 100 and 1000 ng/ml. Further, 10 μ l of goat anti-human IgG (γ)-specific polyclonal antibodies (Sigma) were added to each well at a final concentration of 10 μ g/ml. As a positive control, human recombinant TRAIL proteins (R&D SYSTEMS) with final concentrations of 0.1, 1 and 10 ng/ml were used. A human anti-HSA antibody was used as a negative control. Culturing was performed at 37°C under 5.0% carbon dioxide gas for 48 hours. After culturing, an MTS reagent (Cell Titer 96 AQUEOUS Non-Radioactive Cell Proliferation Assay: Promega) was prepared according to the method described in the instructions. 20 μ l of the reagent was added to each well. After 2 hours of culturing at 37°C under 5.0% carbon dioxide gas, absorbance at a wavelength of 490 nm (with a reference wavelength of 630 nm) was measured using a microplate reader (1420 ARVO multi-label counter: WALLAC). Using the reducibility of the mitochondria as an indicator, the survival rate of the cells was calculated. The survival rate of the cells in each well was calculated using a formula similar to that of Example 7.

Next, the cell-death-inducing activity on HH cells (Tissue Transformation Technologies) was measured using the human anti-TRAIL-R2 monoclonal antibodies obtained in Example 10. First the frozen HH cells were thawed at 37°C, and then prepared at a concentration of 7.5×10^5 /ml using a CM5300 medium (CEDRA). 100 μ l of the suspension was added to each well of a 96-well flat-bottomed plate coated with collagen type I (Beckton Dickinson). After 4.5 hours of culturing at 37°C under 5.0% carbon dioxide gas, medium exchange was performed. After another 24 hours of culturing at 37°C under 5.0% carbon dioxide gas, the medium was exchanged with a

serum-free medium [DMEM medium (Sigma) containing insulin (20 µg/ml, Sigma), glucagon (7 ng/ml, Sigma), hydrocortisone (7.5 µg/ml, Sigma) and human EGF (20 ng/ml, Beckton Dickinson)]. Subsequently, the purified antibodies were added (10 µl/well) at final concentrations of 0.1, 1 and 10 µg/ml, and then 10 µl of goat-anti-human IgG(γ)-specific polyclonal antibodies (Sigma) were added to each well at final concentrations of 10 and 100 µg/ml. As a negative control, human anti-HSA antibodies were used. Culturing was performed at 37°C under 5.0% carbon dioxide gas for 24 hours. After culturing, HH cells were washed twice with PBS, 100 µl of PBS was added to each well, and then Triton X-100 was added (10 µl/well) at a final concentration of 0.8%. The cells were allowed to stand at 37°C for 1 hour, so that living HH cells were lysed. The lysate was transferred (50 µl/well) to a different 96-well flat-bottomed plate, and then subjected to LDH assay. A reagent for LDH assay (CytoTox 96 Non-Radioactive Cytotoxicity Assay: Promega) was prepared according to the method described in the instructions, and then 50 µl of the reagent was added to each well. The plate was protected from light, and then it was allowed to stand at room temperature for 1 hour. A reaction stop solution (1M acetic acid: Promega) was added at 50 µl/well. Absorbance at a wavelength of 492 nm was measured using a microplate reader (1420 ARVO multi-label counter: WALLAC). The survival rate of the cells was calculated using the enzymatic activity of LDH as an indicator. The survival rate of the cells of each well was calculated by a formula similar to that of Example 7.

Furthermore, LD50 values were calculated by the following method using the calculated survival rate. In the graph, the calculated survival rates at each antibody concentration are plotted on the longitudinal axis and the concentrations of the antibodies added to the cells are plotted on the horizontal axis. Plotted dots adjacent to each other are connected to make a curve. A formula expressing this curve was found by a regression calculation. The antibody concentrations corresponding to the survival rate of 50% were

calculated using the formula, thereby obtaining LD50 values.

Fig. 5a to 1 and Table 5 show the results. In Fig. 5, a solid line with solid circles (-●-) expresses normal human hepatocyte, and a dotted line with solid diamond-shaped symbols (–◆–) expresses Colo205 cells. Table 5 shows the cell-death-inducing activity (LD50 value) of the purified human anti-TRAIL-R2 monoclonal antibody on colon carcinoma cells Colo205, and normal human hepatocytes. 2.5×10^3 colon carcinoma cells Colo205, were seeded in 100 μ l of a medium per well of a 96-well flat-bottomed plate, and the purified human anti-TRAIL-R2 monoclonal antibodies were added to the cells on the next day. When the time for the reaction between the cells and the antibody reached 48hours, the LD50 value was obtained. 7.5×10^4 normal cells (human hepatocytes) were seeded in 100 μ l of a medium per well of a 96-well flat-bottomed plate, and the purified human anti-TRAIL-R2 monoclonal antibodies were added to normal cells (human hepatocytes) on the next day. When the time for the reaction between the cells and antibody reached to 24 hours, the LD50 value was obtained. Compared with the negative control, the purified human anti-TRAIL-R2 monoclonal antibody was shown to clearly have activity to induce cell death in Colo205 cells. Furthermore, compared with the human recombinant TRAIL and purified antibody H-48-2, the human hepatocyte toxicity of the purified human anti-TRAIL-R2 monoclonal antibodies E-11-13, L-30-10 and KMTR1 were shown to be low.

Since the hepatocytes showed a survival rate of 50% or more even when 10 μ g/ml L-30-10 was added, the LD50 of L-30-10 was 10 μ g/ml or more. The LD50 was 24 μ g/ml when regression calculation was performed based on a graph on which the antibody concentrations and the survival rates had been plotted. Since the hepatocytes showed a survival rate of 50% or less when 0.1 μ g/ml F-4-8 was added, the LD50 of F-4-8 was 0.1 μ g/ml or less. The LD50 was 0.002 μ g/ml based on a regression calculation performed similarly to that for L-30-10.

Next, the ratio of the LD50 value for normal hepatocytes to that for Colo 205 (showing how many times the LD50 value for normal human hepatocytes is greater than that for Colo205 cells) was measured (N/C ratio). The results were N/C=18.18 (10 times or more greater) in the case of purified antibody E-11-3, N/C=100 (100 times or more greater) in the case of L-30-10. Thus, all the antibodies were shown to be excellent in terms of efficacy and safety (Table 5).

Table 5

Purified human anti-TRAIL-R2 antibody	Normal human hepatocyte LD50 (μg/ml)	Colo205 LD50 (μg/ml)	N/C ratio
E-11-13	2.8	0.11	25.45
F-4-8	0.002	0.02	0.1
H-48-2	0.12	0.15	0.8
L-30-10	24	0.1	240
W-40-5	7.47	0.7	10.7
Human recombinant TRAIL	0.25 ng/ml	2 ng/ml	0.125

By a similar method, the cell-death-inducing activity of the purified human anti-TRAIL-R2 monoclonal antibodies was examined for U251 cells (derived from glioma, Riken Genebank No. RCB0461) and Jurkat cells (derived from T cell lymphomas, Dainippon Pharmaceutical Co., Ltd.). In an experiment for U251 cells, 1.0×10^4 cells were seeded in 100 μl of a medium per well of a 96-well flat-bottomed plate and then cultured at 37°C in the presence of 5% CO₂. The antibodies were added on the next day. After culturing under the above environment for 48 hours, the survival rate of the cells was measured.

In an experiment for Jurkat cells, 4.0×10^4 cells were seeded in 100 μl of a medium per well of a 96-well flat-bottomed plate, and then the antibodies were added. After 48 hours of culturing at 37°C in the presence of 5% CO₂, the survival rate of the cells was measured. The LD50 value (unit: $\mu\text{g/ml}$) of each antibody is as shown below.

LD50 of E-11-13 for U251 cells: 0.3, and for Jurkat cells: 0.1.

LD50 of L-30-10 for U251 cells: 0.17, and for Jurkat cells: 0.13.

LD50 of H-48-2 for U251 cells: 0.24, and for Jurkat cells: 0.07.

LD50 of F-4-8 for U251 cells: 0.03, and for Jurkat cells: 0.004.

LD50 of W-40-5 for U251 cells: 1.0, and for Jurkat cells: 0.48.

In addition for U251 cells, assay was performed with a system wherein a cisplatin solution (NIPPON KAYAKU) with a final concentration of 4 $\mu\text{g/ml}$ was added simultaneously with the antibody.

Example 12 Activity of inducing cell death on cancer cells of purified human anti TRAIL-R2 monoclonal antibody in coexistence of TRAIL

The effect of the purified human anti TRAIL-R2 monoclonal antibody obtained in Example 10 was studied by a method described below. Colo205 cells cultured in RPMI media containing 10% FCS were prepared at a concentration of $2 \times 10^4/\text{ml}$ and 100 μl was added to each well of a 96-well flat-bottomed plate (Beckton Dickinson). After culturing at 37°C under 5.0% carbon dioxide gas for 24 hours, the purified antibodies (10 $\mu\text{l}/\text{ml}$) were added at a concentration of 10 $\mu\text{l}/\text{well}$ such that the final concentration were 0.1, 1 $\mu\text{l}/\text{ml}$, and human recombinant TRAIL protein (R&D SYSTEMS) were added at a concentration of 10 $\mu\text{l}/\text{well}$ such that the final concentration was 1 ng/ml. Human anti-HAS antibody was used as a negative control for the purified antibody. After culturing at 37°C under 5.0% carbon dioxide gas for 48 hours, an MTS reagent (Cell Titer 96 AQUEOUS Non-Radioactive Cell Proliferation Assay: Promega) was prepared according to the method described in the

instructions, and then 20 μ l of the reagent was added to each well. After another 2 hours of culturing at 37°C under 5.0% carbon dioxide gas, absorbance at a wavelength of 490 nm (reference wavelength of 630 nm) was measured using a microplate reader (1420 ARVO multi-label counter: WALLAC). Using the reducibility of mitochondria as an indicator, the survival rate of the cells was calculated. The survival rate of the cells in each well was calculated by the formula described in Example 7.

The results were shown in Figs.6a to 6e. It was revealed that the activity of inducing apoptosis on Colo205 cells in coexistence of TRAIL was observed for purified human anti TRAIL-R2 monoclonal antibodies, F-4-8, H-48-2, W-40-5. To the contrary, as indicated in Figs.6a and 6b, when an antibody was added by itself, the activity of inducing apoptosis was not observed. Accordingly, it is considered that the activity of inducing apoptosis in coexistence of the antibody and TRAIL was brought by TRAIL. L-30-10 did not have effect on the activity of inducing apoptosis on Colo205 cells of TRAIL at any concentration. It is considered that the binding site to a receptor of L-30-10 was different from TRAIL or the affinity of L-30-10 to the receptor was lower than TRAIL and therefore L-30-10 did not inhibit the binding of TRAIL to the receptor. E-11-13 inhibited the activity of inducing apoptosis on Colo205 cells of TRAIL at a final concentration of 1 μ l/ml.

Example 13 Effect of purified human anti-TRAIL-R2 monoclonal antibodies on tumor-bearing mice

The effect of the human anti-TRAIL-R2 monoclonal antibody obtained in Example 10 was examined using a tumor-bearing mouse model according to the following method.

Colo205, colon carcinoma cells, were subcutaneously transplanted in the dorsal areas at 5×10^6 /mouse to 4-week-old Balb/c nude mice (purchased from CLEA Japan). 1 week to 10 days after transplantation, the sizes of tumors

that had adhered were measured. 5 tumor-bearing mice having tumor sizes of 50 to 100 mm³ or 300 mm³ were grouped into a single group. Into the peritoneal cavities of the tumor-bearing mice, the purified antibodies were administered at 1, 4, 20 and 100 µg/mouse (dissolved in 200 µl of PBS), and then the tumor size was measured. The same volume of human anti-HSA antibodies was used as a negative control of the antibody.

Figures 7 to 9 show the results of the above experiments. In the groups where purified human anti-TRAIL-R2 monoclonal antibodies E-11-13, F-4-8, H-48-2, L-30-10 and W-40-5 had been administered at 1 µg/mouse, a regression effect was observed in the group to which H-48-2 had been administered. The anti-tumor effects were lower in descending order of E-11-13, L-30-10, F-4-8 and W-40-5 (Fig. 7). In Fig. 7, when the antibody was administered 3 times on alternate days, growth suppression and a regression effect were observed at least for 13 days when calculated from the initial administration (H-48-2 clone).

In the groups to which E-11-13 had been administered at 4, 20 and 100 µg/mouse, anti-tumor effects were confirmed in all the mice. With a dose of 20 µg/mouse, the highest tumor regression effect was observed (Fig. 8). In Fig. 8, when the antibody was administered 4 times on alternate days, growth suppression and a regression effect were observed at least for 11 days when calculated from the initial administration.

E-11-3 was administered at 20 µg/mouse to a group of 5 tumor-bearing mice where the tumors were 300 mm³. As a result, significant tumor regression was observed (Fig. 9). In Fig. 9, when the antibody was administered 3 times on alternate days, growth suppression and a regression effect were observed at least for 9 days when calculated from the initial administration.

Industrial Applicability

According to the present invention, there is provided a molecule with extremely high safety, which is useful as a prophylactic or therapeutic agent

against disease, in particular malignant tumors, caused by TRAIL-R1 and R2-expressing cells, and which can avoid damage to the liver.

Sequence Listing Free Text

SEQ ID NO: 1: synthetic DNA

SEQ ID NO: 2: synthetic DNA

SEQ ID NO: 3: synthetic DNA

SEQ ID NO: 4: synthetic DNA

SEQ ID NO: 5: synthetic DNA

SEQ ID NO: 6: synthetic DNA

CLAIMS

1. An antibody or a functional fragment thereof, binding to TRAIL-R1 and/or TRAIL-R2.
2. The antibody or the functional fragment thereof of claim 1, having at least one property selected from the following (a) to (c) of:
 - (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;
 - (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and
 - (c) not inducing human hepatocyte toxicity.
3. An antibody or a functional fragment thereof, having all the following properties (a) to (c) of:
 - (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;
 - (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and
 - (c) not inducing human hepatocyte toxicity.
4. The antibody or the functional fragment thereof of claim 2 or 3, which binds to TRAIL-R2, but does not bind to TRAIL-R1.
5. The antibody or the functional fragment thereof of any one of claims 1 to 4, which is a monoclonal antibody produced by a mouse-mouse hybridoma.
6. The antibody or the functional fragment thereof of any one of claims 1 to 5, which is a human antibody.
7. The antibody or the functional fragment thereof of any one of claims 1 to 6, the tumor cells-inducing activity of which is not enhanced under the presence of TRAIL.
8. The antibody or the functional fragment thereof of any one of claims 1 to 6, the tumor cells-inducing activity of which is enhanced under the presence of

TRAIL.

9. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 0.01 $\mu\text{g}/\text{ml}$ or more for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours.

10. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 0.1 $\mu\text{g}/\text{ml}$ or more for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours.
11. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 2 to 10 $\mu\text{g}/\text{ml}$ for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours.
12. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 10 $\mu\text{g}/\text{ml}$ or more for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours.
13. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 100 $\mu\text{g}/\text{ml}$ or less for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.
14. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 10 $\mu\text{g}/\text{ml}$ or less for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.
15. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 0.7 $\mu\text{g}/\text{ml}$ or less for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.
16. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 0.02 to 0.11 $\mu\text{g}/\text{ml}$ for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.
17. The antibody or the functional fragment thereof of any one of claims 1 to 8, having an LD50 value of 0.02 $\mu\text{g}/\text{ml}$ or less for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.
18. The antibody or the functional fragment thereof of any one of claims 1 to 8,

having an LD50 value of 2 to 10 $\mu\text{g}/\text{ml}$ for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours, and having an LD50 value of 0.02 to 0.11 $\mu\text{g}/\text{ml}$ for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

19. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 2 times or more greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

20. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 10 times or more greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

21. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 50 times or more greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

22. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 50 to 100 times greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

23. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 100 times or more greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

24. The antibody or the functional fragment thereof of any one of claims 1 to 8, wherein the LD50 value for human hepatocytes when the number of cells is 7.5×10^4 and the reaction time is 24 hours is 100 to 1000 times greater than the LD50 value for carcinoma cells when the number of cells is 2.5×10^3 and the reaction time is 48 hours.

24. The antibody or the functional fragment thereof of any one of claims 2, 3, 7, 8 and 13 to 23, wherein the carcinoma cells are Colo205 cells.

25. The antibody or the functional fragment thereof of any one of claims 2, 3, 7 and 8, wherein the carcinoma cells are Colo205 cells, U251 cells or Jurkat cells.

26. The antibody or the functional fragment thereof of any one of claims 1 to 25, which can suppress tumor growth or regress tumors.

27. The antibody or the functional fragment thereof of claim 26, wherein the tumor is at least one tumor selected from the group consisting of colon cancer, colorectal cancer, lung cancer, breast cancer, brain tumor, malignant melanoma, renal cell carcinoma, leukemia, lymphomas, T cell lymphomas, gastric cancer, pancreas cancer, cervical cancer, endometrial carcinoma, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, cutaneous cancer, urinary tract carcinoma, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecomatosis, androblastoma, endometrium hyperplasy, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, angioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendrolioma, medulloblastoma, ganglioneuroblastoma, glioma, rhabdomyosarcoma, hamartoblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma, Wilms tumor.

28. The antibody or the functional fragment thereof of claim 26, wherein the tumor is derived from Colo205 cells transplanted in a nude mouse.

29. The antibody or the functional fragment thereof of any one of claims 26 to 28, wherein a period during which tumor growth can be suppressed or tumor regression can be achieved is at least 9 days.

30. The antibody or the functional fragment thereof of any one of claims 26 to 29, wherein the dose of the antibody or the functional fragment thereof is 100 $\mu\text{g}/\text{body}$ or 5 mg/kg .

31. The antibody or the functional fragment thereof of any one of claims 26 to 29, wherein the dose of the antibody or the functional fragment thereof is 20 $\mu\text{g}/\text{body}$ or 1 mg/kg .

32. The antibody or the functional fragment thereof of any one of claims 26 to 29, wherein the dose of the antibody or the functional fragment thereof is 4 $\mu\text{g}/\text{body}$ or 200 $\mu\text{g}/\text{kg}$.

33. The antibody or the functional fragment thereof of any one of claims 26 to 29, wherein the dose of the antibody or the functional fragment thereof is 1 $\mu\text{g}/\text{body}$ or 50 $\mu\text{g}/\text{kg}$.

34. The antibody or the functional fragment thereof of any one of claims 1 to 33, which is an immunoglobulin G antibody.

35. An antibody or a functional fragment thereof binding to TRAIL-R1 or TRAIL-R2, which is produced by a hybridoma E-11-13, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-12, F-4-8, or G-3-10.

36. An antibody or a functional fragment thereof binding to TRAIL-R1 or TRAIL-R2, which is produced by a hybridoma H-48-2 with the accession number of FERM BP-7599, a hybridoma E-11-13 with the accession number of FERM BP-7698, a hybridoma F-4-8 with the accession number of FERM BP-7699, or a hybridoma L-30-10 with the accession number of FERM BP-7700.

37. A hybridoma producing monoclonal antibodies that bind to TRAIL-R2, which is selected from the group consisting of E-11-13, H-48-2, L-30-10, N-18-12, W-40-5, X-14-4, X-51-12, F-4-8, and G-3-10.

38. A hybridoma producing monoclonal antibodies that bind to TRAIL-R2, which is selected from a hybridoma H-48-2 with the accession number of FERM BP-7599, a hybridoma E-11-13 with the accession number of FERM BP-7698, a

hybridoma F-4-8 with the accession number of FERM BP-7699 and a hybridoma L-30-10 with the accession number of FERM BP-7700.

39. A method for producing anti-TRAIL-R2 monoclonal antibodies, comprising culturing the hybridoma of claim 37 or 38, and collecting the antibodies binding to TRAIL-R2 from the obtained culture product.

40. A method for producing anti-TRAIL-R2 monoclonal antibodies, comprising isolating a gene encoding an anti-TRAIL-R2 monoclonal antibody from the hybridoma of claim 37 or 38, constructing an expression vector having the gene, introducing the expression vector into a host to express the monoclonal antibody, and collecting anti-TRAIL-R2 monoclonal antibodies from the obtained host, or the culture supernatant or the secretion of the host.

41. The production method of claim 40, wherein the host is any host selected from the group consisting of *Escherichia coli*, yeast cells, insect cells, mammalian cells and plant cells, and mammals.

42. A method for producing anti-TRAIL-R2 antibody which does not have hepatocyte toxicity, comprising selecting an antibody which does not bind to TRAIL-R1 from the population of antibodies which bind to TRAIL-R2.

43. A prophylactic or therapeutic agent against tumors, comprising as an active ingredient the antibody or the functional fragment thereof of any one of claims 1 to 36.

44. The prophylactic or therapeutic agent of claim 43, wherein the tumor is any one tumor selected from the group consisting of colon cancer, colorectal cancer, lung cancer, breast cancer, brain tumor, malignant melanoma, renal cell carcinoma, leukemia, lymphomas, T cell lymphomas, gastric cancer, pancreas cancer, cervical cancer, endometrial carcinoma, ovarian cancer, esophageal cancer, liver cancer, head and neck squamous cell carcinoma, cutaneous cancer, urinary tract carcinoma, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecomatosis, androblastoma, endometrium hyperplasy, endometriosis, embryoma, fibrosarcoma, Kaposi's sarcoma, hemangioma,

cavernous hemangioma, angioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendrogloma, medulloblastoma, ganglioneuroblastoma, glioma, rhabdomyosarcoma, hamartoblastoma, osteogenic sarcoma, leiomyosarcoma, thyroid sarcoma, Wilms tumor.

ABSTRACT

The invention provides an anti-TRAIL-R1 and TRAIL-R2 antibody.

Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of:

- (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;
- (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and
- (c) not inducing human hepatocyte toxicity.

SEQUENCE LISTING

<110> KIRIN BEER KABUSHIKI KAISHA

<120> ANTI TRAIL-R ANTIBODY

<130> P01-0743

<140>

<141>

<150> JP2001-150213

<151> 2001-05-18

<150> JP2001-243040

<151> 2001-08-09

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic DNA

<400> 1

cacgaattca ccatggcgcc accaccagct

30

<210> 2

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic DNA

<400> 2

tttctcgagg cggccgctta tcactccaag gacacggcag agcctgtg

48

<210> 3
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic DNA

<400> 3
cacgaattcg ccaccatgga acaacgggga cag 33

<210> 4
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic DNA

<400> 4
tttctcgagg cggccgctca ttaggacatg gcagagtctg cattacct 48

<210> 5
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic DNA

<400> 5
ttctacgagc ggcttatcac agcctcctcc tctgaga 37

<210> 6
<211> 40
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA

<400> 6

ttctacgagc ggccgcttat cacaagtctg caaagtcatc

40

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9

